<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:dc="http://purl.org/dc/elements/1.1/"><channel><title>PeptideScanner What changed</title><link>https://peptidescanner.com/whats-new/</link><description>Follow selected PeptideScanner profile, review, study, official-source-note and source-record additions with their source, review and site dates kept separate.</description><language>en-us</language><atom:link href="https://peptidescanner.com/feeds/whats-new.xml" rel="self" type="application/rss+xml"/><item><title>ClinicalTrials.gov record NCT03606577</title><link>https://peptidescanner.com/stories/clinicaltrials-gov-nct03606577-carfilzomib/</link><guid isPermaLink="false">peptidescanner:whats-new:source-record:clinicaltrials-gov-nct03606577-carfilzomib:v1</guid><description>PeptideScanner retained ClinicalTrials.gov record NCT03606577 at 2026-11-17T13:28:01.467Z. Its registry update date was 2026-11-12, and PeptideScanner&apos;s reviewed identity mapping was carfilzomib. Site addition: 2026-11-17. Source date: Cited source date 2026-11-12. Source checked: 2026-11-17. Limits: This is a selected source-linked record. Its source date and collection date stay separate; inclusion does not establish that the source is current, complete, safe, or effective. Sources: ClinicalTrials.gov record NCT03606577 · retained source version 2026-11-12:dfccdc11c35cf0222f1eb4cbae36ff75c546dd07d7f0cf9cd1053b6f0ee4e29c (https://clinicaltrials.gov/study/NCT03606577)</description><dc:date>2026-11-17</dc:date><category>Source record added</category><category>carfilzomib</category></item><item><title>ClinicalTrials.gov record NCT05344469</title><link>https://peptidescanner.com/stories/clinicaltrials-gov-nct05344469-glatiramer-acetate/</link><guid isPermaLink="false">peptidescanner:whats-new:source-record:clinicaltrials-gov-nct05344469-glatiramer-acetate:v1</guid><description>PeptideScanner retained ClinicalTrials.gov record NCT05344469 at 2026-11-17T13:28:01.467Z. Its registry update date was 2026-11-16, and PeptideScanner&apos;s reviewed identity mapping was glatiramer-acetate. Site addition: 2026-11-17. Source date: Cited source date 2026-11-16. Source checked: 2026-11-17. Limits: This is a selected source-linked record. Its source date and collection date stay separate; inclusion does not establish that the source is current, complete, safe, or effective. Sources: ClinicalTrials.gov record NCT05344469 · retained source version 2026-11-16:4df425e304d4cd3eda46eabb081d4799f7679920d5ce46ab94b3e04d7c5d680a (https://clinicaltrials.gov/study/NCT05344469)</description><dc:date>2026-11-17</dc:date><category>Source record added</category><category>glatiramer-acetate</category></item><item><title>ClinicalTrials.gov record NCT06152575</title><link>https://peptidescanner.com/stories/clinicaltrials-gov-nct06152575-carfilzomib/</link><guid isPermaLink="false">peptidescanner:whats-new:source-record:clinicaltrials-gov-nct06152575-carfilzomib:v1</guid><description>PeptideScanner retained ClinicalTrials.gov record NCT06152575 at 2026-11-17T13:28:01.467Z. Its registry update date was 2026-11-12, and PeptideScanner&apos;s reviewed identity mapping was carfilzomib. Site addition: 2026-11-17. Source date: Cited source date 2026-11-12. Source checked: 2026-11-17. Limits: This is a selected source-linked record. Its source date and collection date stay separate; inclusion does not establish that the source is current, complete, safe, or effective. Sources: ClinicalTrials.gov record NCT06152575 · retained source version 2026-11-12:b40f3be6bfe9bf8a5151b90016cc17b95f069b01bcff5119e0510e701ab5382e (https://clinicaltrials.gov/study/NCT06152575)</description><dc:date>2026-11-17</dc:date><category>Source record added</category><category>carfilzomib</category></item><item><title>ClinicalTrials.gov record NCT07555938</title><link>https://peptidescanner.com/stories/clinicaltrials-gov-nct07555938-carfilzomib/</link><guid isPermaLink="false">peptidescanner:whats-new:source-record:clinicaltrials-gov-nct07555938-carfilzomib:v1</guid><description>PeptideScanner retained ClinicalTrials.gov record NCT07555938 at 2026-11-17T13:28:01.467Z. Its registry update date was 2026-11-10, and PeptideScanner&apos;s reviewed identity mapping was carfilzomib. Site addition: 2026-11-17. Source date: Cited source date 2026-11-10. Source checked: 2026-11-17. Limits: This is a selected source-linked record. Its source date and collection date stay separate; inclusion does not establish that the source is current, complete, safe, or effective. Sources: ClinicalTrials.gov record NCT07555938 · retained source version 2026-11-10:a49c9796a93023e4be137c8f04eba3fdeb0a373f7b1371acc7eb4b24b3b421de (https://clinicaltrials.gov/study/NCT07555938)</description><dc:date>2026-11-17</dc:date><category>Source record added</category><category>carfilzomib</category></item><item><title>ClinicalTrials.gov record NCT07715903</title><link>https://peptidescanner.com/stories/clinicaltrials-gov-nct07715903-carfilzomib/</link><guid isPermaLink="false">peptidescanner:whats-new:source-record:clinicaltrials-gov-nct07715903-carfilzomib:v1</guid><description>PeptideScanner retained ClinicalTrials.gov record NCT07715903 at 2026-11-17T13:28:01.467Z. Its registry update date was 2026-11-16, and PeptideScanner&apos;s reviewed identity mapping was carfilzomib. Site addition: 2026-11-17. Source date: Cited source date 2026-11-16. Source checked: 2026-11-17. Limits: This is a selected source-linked record. Its source date and collection date stay separate; inclusion does not establish that the source is current, complete, safe, or effective. Sources: ClinicalTrials.gov record NCT07715903 · retained source version 2026-11-16:26eebf96af2f6c9a1b392487c8c78d7a7fb6645919439c2f5c7b0aadf1c11585 (https://clinicaltrials.gov/study/NCT07715903)</description><dc:date>2026-11-17</dc:date><category>Source record added</category><category>carfilzomib</category></item><item><title>Development and Validation of a Stability-Indicating HPLC Method for Degarelix and Characterization of Its Degradation Impurities Using LC-MS, 1H NMR, and FTIR Techniques.</title><link>https://peptidescanner.com/stories/pubmed-pmid-43041099-degarelix/</link><guid isPermaLink="false">peptidescanner:whats-new:source-record:pubmed-pmid-43041099-degarelix:v1</guid><description>PubMed lists PMID 43041099 in Biomedical chromatography : BMC as Journal Article, with publication-date metadata of 2027-01 (month precision). PeptideScanner associated the retained record with the identity slug degarelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article&apos;s findings. Site addition: 2026-11-17. Source date: Cited source date 2026-11-17. Source checked: 2026-11-17. Limits: This is a selected source-linked record. Its source date and collection date stay separate; inclusion does not establish that the source is current, complete, safe, or effective. Sources: Development and Validation of a Stability-Indicating HPLC Method for Degarelix and Characterization of Its Degradation Impurities Using LC-MS, 1H NMR, and FTIR Techniques. · retained source version 1:2026-11-17:current:435b8b15458aa919dd3758a413e19032c9f76b6b2bc81b65f4d46e0debb20935 (https://pubmed.ncbi.nlm.nih.gov/43041099/)</description><dc:date>2026-11-17</dc:date><category>Source record added</category><category>degarelix</category></item><item><title>Drugs@FDA application ANDA090218</title><link>https://peptidescanner.com/stories/fda-drugs-anda090218/</link><guid isPermaLink="false">peptidescanner:whats-new:source-record:fda-drugs-anda090218:v1</guid><description>The official Drugs@FDA dataset lists original submission 1 for ANDA 090218 with status AP dated 2015-04-16, and names glatiramer acetate among the application record&apos;s active ingredients. Site addition: 2026-11-17. Source date: Cited source date 2015-04-16. Source checked: 2026-11-17. Limits: This is a selected source-linked record. Its source date and collection date stay separate; inclusion does not establish that the source is current, complete, safe, or effective. Sources: Drugs@FDA application ANDA090218 · original submission status AP · 2015-04-16 · dataset 2026-11-16 (https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA090218%22&amp;limit=1)</description><dc:date>2026-11-17</dc:date><category>Source record added</category><category>glatiramer-acetate</category></item><item><title>Drugs@FDA application ANDA091646</title><link>https://peptidescanner.com/stories/fda-drugs-anda091646/</link><guid isPermaLink="false">peptidescanner:whats-new:source-record:fda-drugs-anda091646:v1</guid><description>The official Drugs@FDA dataset lists original submission 1 for ANDA 091646 with status AP dated 2017-10-03, and names glatiramer acetate among the application record&apos;s active ingredients. Site addition: 2026-11-17. Source date: Cited source date 2017-10-03. Source checked: 2026-11-17. Limits: This is a selected source-linked record. Its source date and collection date stay separate; inclusion does not establish that the source is current, complete, safe, or effective. Sources: Drugs@FDA application ANDA091646 · original submission status AP · 2017-10-03 · dataset 2026-11-16 (https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA091646%22&amp;limit=1)</description><dc:date>2026-11-17</dc:date><category>Source record added</category><category>glatiramer-acetate</category></item><item><title>Drugs@FDA application ANDA203857</title><link>https://peptidescanner.com/stories/fda-drugs-anda203857/</link><guid isPermaLink="false">peptidescanner:whats-new:source-record:fda-drugs-anda203857:v1</guid><description>The official Drugs@FDA dataset lists original submission 1 for ANDA 203857 with status AP dated 2024-09-25, and names glatiramer acetate among the application record&apos;s active ingredients. Site addition: 2026-11-17. Source date: Cited source date 2024-09-25. Source checked: 2026-11-17. Limits: This is a selected source-linked record. Its source date and collection date stay separate; inclusion does not establish that the source is current, complete, safe, or effective. Sources: Drugs@FDA application ANDA203857 · original submission status AP · 2024-09-25 · dataset 2026-11-16 (https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA203857%22&amp;limit=1)</description><dc:date>2026-11-17</dc:date><category>Source record added</category><category>glatiramer-acetate</category></item><item><title>Drugs@FDA application ANDA206873</title><link>https://peptidescanner.com/stories/fda-drugs-anda206873/</link><guid isPermaLink="false">peptidescanner:whats-new:source-record:fda-drugs-anda206873:v1</guid><description>The official Drugs@FDA dataset lists original submission 1 for ANDA 206873 with status AP dated 2024-09-25, and names glatiramer acetate among the application record&apos;s active ingredients. Site addition: 2026-11-17. Source date: Cited source date 2024-09-25. Source checked: 2026-11-17. Limits: This is a selected source-linked record. Its source date and collection date stay separate; inclusion does not establish that the source is current, complete, safe, or effective. Sources: Drugs@FDA application ANDA206873 · original submission status AP · 2024-09-25 · dataset 2026-11-16 (https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA206873%22&amp;limit=1)</description><dc:date>2026-11-17</dc:date><category>Source record added</category><category>glatiramer-acetate</category></item><item><title>Drugs@FDA application ANDA206921</title><link>https://peptidescanner.com/stories/fda-drugs-anda206921/</link><guid isPermaLink="false">peptidescanner:whats-new:source-record:fda-drugs-anda206921:v1</guid><description>The official Drugs@FDA dataset lists original submission 1 for ANDA 206921 with status AP dated 2018-02-12, and names glatiramer acetate among the application record&apos;s active ingredients. Site addition: 2026-11-17. Source date: Cited source date 2018-02-12. Source checked: 2026-11-17. Limits: This is a selected source-linked record. Its source date and collection date stay separate; inclusion does not establish that the source is current, complete, safe, or effective. Sources: Drugs@FDA application ANDA206921 · original submission status AP · 2018-02-12 · dataset 2026-11-16 (https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA206921%22&amp;limit=1)</description><dc:date>2026-11-17</dc:date><category>Source record added</category><category>glatiramer-acetate</category></item><item><title>Drugs@FDA application ANDA206936</title><link>https://peptidescanner.com/stories/fda-drugs-anda206936/</link><guid isPermaLink="false">peptidescanner:whats-new:source-record:fda-drugs-anda206936:v1</guid><description>The official Drugs@FDA dataset lists original submission 1 for ANDA 206936 with status AP dated 2017-10-03, and names glatiramer acetate among the application record&apos;s active ingredients. Site addition: 2026-11-17. Source date: Cited source date 2017-10-03. Source checked: 2026-11-17. Limits: This is a selected source-linked record. Its source date and collection date stay separate; inclusion does not establish that the source is current, complete, safe, or effective. Sources: Drugs@FDA application ANDA206936 · original submission status AP · 2017-10-03 · dataset 2026-11-16 (https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA206936%22&amp;limit=1)</description><dc:date>2026-11-17</dc:date><category>Source record added</category><category>glatiramer-acetate</category></item><item><title>Drugs@FDA application ANDA208468</title><link>https://peptidescanner.com/stories/fda-drugs-anda208468/</link><guid isPermaLink="false">peptidescanner:whats-new:source-record:fda-drugs-anda208468:v1</guid><description>The official Drugs@FDA dataset lists original submission 1 for ANDA 208468 with status AP dated 2025-05-07, and names glatiramer acetate among the application record&apos;s active ingredients. Site addition: 2026-11-17. Source date: Cited source date 2025-05-07. Source checked: 2026-11-17. Limits: This is a selected source-linked record. Its source date and collection date stay separate; inclusion does not establish that the source is current, complete, safe, or effective. Sources: Drugs@FDA application ANDA208468 · original submission status AP · 2025-05-07 · dataset 2026-11-16 (https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA208468%22&amp;limit=1)</description><dc:date>2026-11-17</dc:date><category>Source record added</category><category>glatiramer-acetate</category></item><item><title>Drugs@FDA application ANDA209330</title><link>https://peptidescanner.com/stories/fda-drugs-anda209330/</link><guid isPermaLink="false">peptidescanner:whats-new:source-record:fda-drugs-anda209330:v1</guid><description>The official Drugs@FDA dataset lists original submission 1 for ANDA 209330 with status AP dated 2021-06-11, and names carfilzomib among the application record&apos;s active ingredients. Site addition: 2026-11-17. Source date: Cited source date 2021-06-11. Source checked: 2026-11-17. Limits: This is a selected source-linked record. Its source date and collection date stay separate; inclusion does not establish that the source is current, complete, safe, or effective. Sources: Drugs@FDA application ANDA209330 · original submission status AP · 2021-06-11 · dataset 2026-11-16 (https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA209330%22&amp;limit=1)</description><dc:date>2026-11-17</dc:date><category>Source record added</category><category>carfilzomib</category></item><item><title>Drugs@FDA application ANDA209422</title><link>https://peptidescanner.com/stories/fda-drugs-anda209422/</link><guid isPermaLink="false">peptidescanner:whats-new:source-record:fda-drugs-anda209422:v1</guid><description>The official Drugs@FDA dataset lists original submission 1 for ANDA 209422 with status AP dated 2019-09-09, and names carfilzomib among the application record&apos;s active ingredients. Site addition: 2026-11-17. Source date: Cited source date 2019-09-09. Source checked: 2026-11-17. Limits: This is a selected source-linked record. Its source date and collection date stay separate; inclusion does not establish that the source is current, complete, safe, or effective. Sources: Drugs@FDA application ANDA209422 · original submission status AP · 2019-09-09 · dataset 2026-11-16 (https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA209422%22&amp;limit=1)</description><dc:date>2026-11-17</dc:date><category>Source record added</category><category>carfilzomib</category></item><item><title>Drugs@FDA application ANDA209425</title><link>https://peptidescanner.com/stories/fda-drugs-anda209425/</link><guid isPermaLink="false">peptidescanner:whats-new:source-record:fda-drugs-anda209425:v1</guid><description>The official Drugs@FDA dataset lists original submission 1 for ANDA 209425 with status AP dated 2020-03-16, and names carfilzomib among the application record&apos;s active ingredients. Site addition: 2026-11-17. Source date: Cited source date 2020-03-16. Source checked: 2026-11-17. Limits: This is a selected source-linked record. Its source date and collection date stay separate; inclusion does not establish that the source is current, complete, safe, or effective. Sources: Drugs@FDA application ANDA209425 · original submission status AP · 2020-03-16 · dataset 2026-11-16 (https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA209425%22&amp;limit=1)</description><dc:date>2026-11-17</dc:date><category>Source record added</category><category>carfilzomib</category></item><item><title>Drugs@FDA application ANDA209526</title><link>https://peptidescanner.com/stories/fda-drugs-anda209526/</link><guid isPermaLink="false">peptidescanner:whats-new:source-record:fda-drugs-anda209526:v1</guid><description>The official Drugs@FDA dataset lists original submission 1 for ANDA 209526 with status AP dated 2026-07-20, and names carfilzomib among the application record&apos;s active ingredients. Site addition: 2026-11-17. Source date: Cited source date 2026-07-20. Source checked: 2026-11-17. Limits: This is a selected source-linked record. Its source date and collection date stay separate; inclusion does not establish that the source is current, complete, safe, or effective. Sources: Drugs@FDA application ANDA209526 · original submission status AP · 2026-07-20 · dataset 2026-11-16 (https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA209526%22&amp;limit=1)</description><dc:date>2026-11-17</dc:date><category>Source record added</category><category>carfilzomib</category></item><item><title>Drugs@FDA application ANDA211185</title><link>https://peptidescanner.com/stories/fda-drugs-anda211185/</link><guid isPermaLink="false">peptidescanner:whats-new:source-record:fda-drugs-anda211185:v1</guid><description>The official Drugs@FDA dataset lists original submission 1 for ANDA 211185 with status AP dated 2020-03-20, and names carfilzomib among the application record&apos;s active ingredients. Site addition: 2026-11-17. Source date: Cited source date 2020-03-20. Source checked: 2026-11-17. Limits: This is a selected source-linked record. Its source date and collection date stay separate; inclusion does not establish that the source is current, complete, safe, or effective. Sources: Drugs@FDA application ANDA211185 · original submission status AP · 2020-03-20 · dataset 2026-11-16 (https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA211185%22&amp;limit=1)</description><dc:date>2026-11-17</dc:date><category>Source record added</category><category>carfilzomib</category></item><item><title>Drugs@FDA application ANDA213382</title><link>https://peptidescanner.com/stories/fda-drugs-anda213382/</link><guid isPermaLink="false">peptidescanner:whats-new:source-record:fda-drugs-anda213382:v1</guid><description>The official Drugs@FDA dataset lists original submission 1 for ANDA 213382 with status AP dated 2026-02-11, and names glatiramer acetate among the application record&apos;s active ingredients. Site addition: 2026-11-17. Source date: Cited source date 2026-02-11. Source checked: 2026-11-17. Limits: This is a selected source-linked record. Its source date and collection date stay separate; inclusion does not establish that the source is current, complete, safe, or effective. Sources: Drugs@FDA application ANDA213382 · original submission status AP · 2026-02-11 · dataset 2026-11-16 (https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA213382%22&amp;limit=1)</description><dc:date>2026-11-17</dc:date><category>Source record added</category><category>glatiramer-acetate</category></item><item><title>Drugs@FDA application ANDA214022</title><link>https://peptidescanner.com/stories/fda-drugs-anda214022/</link><guid isPermaLink="false">peptidescanner:whats-new:source-record:fda-drugs-anda214022:v1</guid><description>The official Drugs@FDA dataset lists original submission 1 for ANDA 214022 with status AP dated 2026-02-11, and names glatiramer acetate among the application record&apos;s active ingredients. Site addition: 2026-11-17. Source date: Cited source date 2026-02-11. Source checked: 2026-11-17. Limits: This is a selected source-linked record. Its source date and collection date stay separate; inclusion does not establish that the source is current, complete, safe, or effective. Sources: Drugs@FDA application ANDA214022 · original submission status AP · 2026-02-11 · dataset 2026-11-16 (https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA214022%22&amp;limit=1)</description><dc:date>2026-11-17</dc:date><category>Source record added</category><category>glatiramer-acetate</category></item><item><title>Drugs@FDA application ANDA214741</title><link>https://peptidescanner.com/stories/fda-drugs-anda214741/</link><guid isPermaLink="false">peptidescanner:whats-new:source-record:fda-drugs-anda214741:v1</guid><description>The official Drugs@FDA dataset lists original submission 1 for ANDA 214741 with status AP dated 2025-12-31, and names glatiramer acetate among the application record&apos;s active ingredients. Site addition: 2026-11-17. Source date: Cited source date 2025-12-31. Source checked: 2026-11-17. Limits: This is a selected source-linked record. Its source date and collection date stay separate; inclusion does not establish that the source is current, complete, safe, or effective. Sources: Drugs@FDA application ANDA214741 · original submission status AP · 2025-12-31 · dataset 2026-11-16 (https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA214741%22&amp;limit=1)</description><dc:date>2026-11-17</dc:date><category>Source record added</category><category>glatiramer-acetate</category></item><item><title>Drugs@FDA application ANDA217591</title><link>https://peptidescanner.com/stories/fda-drugs-anda217591/</link><guid isPermaLink="false">peptidescanner:whats-new:source-record:fda-drugs-anda217591:v1</guid><description>The official Drugs@FDA dataset lists original submission 1 for ANDA 217591 with status AP dated 2025-11-10, and names dalbavancin hydrochloride among the application record&apos;s active ingredients. Site addition: 2026-11-17. Source date: Cited source date 2025-11-10. Source checked: 2026-11-17. Limits: This is a selected source-linked record. Its source date and collection date stay separate; inclusion does not establish that the source is current, complete, safe, or effective. Sources: Drugs@FDA application ANDA217591 · original submission status AP · 2025-11-10 · dataset 2026-11-16 (https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA217591%22&amp;limit=1)</description><dc:date>2026-11-17</dc:date><category>Source record added</category><category>dalbavancin</category></item><item><title>Drugs@FDA application ANDA218602</title><link>https://peptidescanner.com/stories/fda-drugs-anda218602/</link><guid isPermaLink="false">peptidescanner:whats-new:source-record:fda-drugs-anda218602:v1</guid><description>The official Drugs@FDA dataset lists original submission 1 for ANDA 218602 with status AP dated 2026-02-26, and names dalbavancin hydrochloride among the application record&apos;s active ingredients. Site addition: 2026-11-17. Source date: Cited source date 2026-02-26. Source checked: 2026-11-17. Limits: This is a selected source-linked record. Its source date and collection date stay separate; inclusion does not establish that the source is current, complete, safe, or effective. Sources: Drugs@FDA application ANDA218602 · original submission status AP · 2026-02-26 · dataset 2026-11-16 (https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA218602%22&amp;limit=1)</description><dc:date>2026-11-17</dc:date><category>Source record added</category><category>dalbavancin</category></item><item><title>Drugs@FDA application ANDA218929</title><link>https://peptidescanner.com/stories/fda-drugs-anda218929/</link><guid isPermaLink="false">peptidescanner:whats-new:source-record:fda-drugs-anda218929:v1</guid><description>The official Drugs@FDA dataset lists original submission 1 for ANDA 218929 with status AP dated 2025-11-26, and names dalbavancin hydrochloride among the application record&apos;s active ingredients. Site addition: 2026-11-17. Source date: Cited source date 2025-11-26. Source checked: 2026-11-17. Limits: This is a selected source-linked record. Its source date and collection date stay separate; inclusion does not establish that the source is current, complete, safe, or effective. Sources: Drugs@FDA application ANDA218929 · original submission status AP · 2025-11-26 · dataset 2026-11-16 (https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA218929%22&amp;limit=1)</description><dc:date>2026-11-17</dc:date><category>Source record added</category><category>dalbavancin</category></item><item><title>Drugs@FDA application ANDA219465</title><link>https://peptidescanner.com/stories/fda-drugs-anda219465/</link><guid isPermaLink="false">peptidescanner:whats-new:source-record:fda-drugs-anda219465:v1</guid><description>The official Drugs@FDA dataset lists original submission 1 for ANDA 219465 with status AP dated 2025-10-23, and names dalbavancin hydrochloride among the application record&apos;s active ingredients. Site addition: 2026-11-17. Source date: Cited source date 2025-10-23. Source checked: 2026-11-17. Limits: This is a selected source-linked record. Its source date and collection date stay separate; inclusion does not establish that the source is current, complete, safe, or effective. Sources: Drugs@FDA application ANDA219465 · original submission status AP · 2025-10-23 · dataset 2026-11-16 (https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA219465%22&amp;limit=1)</description><dc:date>2026-11-17</dc:date><category>Source record added</category><category>dalbavancin</category></item><item><title>Drugs@FDA application ANDA219604</title><link>https://peptidescanner.com/stories/fda-drugs-anda219604/</link><guid isPermaLink="false">peptidescanner:whats-new:source-record:fda-drugs-anda219604:v1</guid><description>The official Drugs@FDA dataset lists original submission 1 for ANDA 219604 with status AP dated 2026-06-04, and names dalbavancin hydrochloride among the application record&apos;s active ingredients. Site addition: 2026-11-17. Source date: Cited source date 2026-06-04. Source checked: 2026-11-17. Limits: This is a selected source-linked record. Its source date and collection date stay separate; inclusion does not establish that the source is current, complete, safe, or effective. Sources: Drugs@FDA application ANDA219604 · original submission status AP · 2026-06-04 · dataset 2026-11-16 (https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA219604%22&amp;limit=1)</description><dc:date>2026-11-17</dc:date><category>Source record added</category><category>dalbavancin</category></item><item><title>Drugs@FDA application BLA021839</title><link>https://peptidescanner.com/stories/fda-drugs-bla021839/</link><guid isPermaLink="false">peptidescanner:whats-new:source-record:fda-drugs-bla021839:v1</guid><description>The official Drugs@FDA dataset lists original submission 1 for BLA 021839 with status AP dated 2005-08-30, and names mecasermin recombinant among the application record&apos;s active ingredients. Site addition: 2026-11-17. Source date: Cited source date 2005-08-30. Source checked: 2026-11-17. Limits: This is a selected source-linked record. Its source date and collection date stay separate; inclusion does not establish that the source is current, complete, safe, or effective. Sources: Drugs@FDA application BLA021839 · original submission status AP · 2005-08-30 · dataset 2026-11-16 (https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22BLA021839%22&amp;limit=1)</description><dc:date>2026-11-17</dc:date><category>Source record added</category><category>mecasermin</category></item><item><title>Drugs@FDA application BLA125390</title><link>https://peptidescanner.com/stories/fda-drugs-bla125390/</link><guid isPermaLink="false">peptidescanner:whats-new:source-record:fda-drugs-bla125390:v1</guid><description>The official Drugs@FDA dataset lists original submission 1 for BLA 125390 with status AP dated 2014-02-24, and names metreleptin among the application record&apos;s active ingredients. Site addition: 2026-11-17. Source date: Cited source date 2014-02-24. Source checked: 2026-11-17. Limits: This is a selected source-linked record. Its source date and collection date stay separate; inclusion does not establish that the source is current, complete, safe, or effective. Sources: Drugs@FDA application BLA125390 · original submission status AP · 2014-02-24 · dataset 2026-11-16 (https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22BLA125390%22&amp;limit=1)</description><dc:date>2026-11-17</dc:date><category>Source record added</category><category>metreleptin</category></item><item><title>Drugs@FDA application BLA125431</title><link>https://peptidescanner.com/stories/fda-drugs-bla125431/</link><guid isPermaLink="false">peptidescanner:whats-new:source-record:fda-drugs-bla125431:v1</guid><description>The official Drugs@FDA dataset lists original submission 1 for BLA 125431 with status AP dated 2014-04-15, and names albiglutide among the application record&apos;s active ingredients. Site addition: 2026-11-17. Source date: Cited source date 2014-04-15. Source checked: 2026-11-17. Limits: This is a selected source-linked record. Its source date and collection date stay separate; inclusion does not establish that the source is current, complete, safe, or effective. Sources: Drugs@FDA application BLA125431 · original submission status AP · 2014-04-15 · dataset 2026-11-16 (https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22BLA125431%22&amp;limit=1)</description><dc:date>2026-11-17</dc:date><category>Source record added</category><category>albiglutide</category></item><item><title>Drugs@FDA application NDA018123</title><link>https://peptidescanner.com/stories/fda-drugs-nda018123/</link><guid isPermaLink="false">peptidescanner:whats-new:source-record:fda-drugs-nda018123:v1</guid><description>The official Drugs@FDA dataset lists original submission 1 for NDA 018123 with status AP dated 1982-09-30, and names gonadorelin hydrochloride among the application record&apos;s active ingredients. Site addition: 2026-11-17. Source date: Cited source date 1982-09-30. Source checked: 2026-11-17. Limits: This is a selected source-linked record. Its source date and collection date stay separate; inclusion does not establish that the source is current, complete, safe, or effective. Sources: Drugs@FDA application NDA018123 · original submission status AP · 1982-09-30 · dataset 2026-11-16 (https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA018123%22&amp;limit=1)</description><dc:date>2026-11-17</dc:date><category>Source record added</category><category>gonadorelin</category></item><item><title>Drugs@FDA application NDA020622</title><link>https://peptidescanner.com/stories/fda-drugs-nda020622/</link><guid isPermaLink="false">peptidescanner:whats-new:source-record:fda-drugs-nda020622:v1</guid><description>The official Drugs@FDA dataset lists original submission 1 for NDA 020622 with status AP dated 1996-12-20, and names glatiramer acetate among the application record&apos;s active ingredients. Site addition: 2026-11-17. Source date: Cited source date 1996-12-20. Source checked: 2026-11-17. Limits: This is a selected source-linked record. Its source date and collection date stay separate; inclusion does not establish that the source is current, complete, safe, or effective. Sources: Drugs@FDA application NDA020622 · original submission status AP · 1996-12-20 · dataset 2026-11-16 (https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA020622%22&amp;limit=1)</description><dc:date>2026-11-17</dc:date><category>Source record added</category><category>glatiramer-acetate</category></item><item><title>Drugs@FDA application NDA021883</title><link>https://peptidescanner.com/stories/fda-drugs-nda021883/</link><guid isPermaLink="false">peptidescanner:whats-new:source-record:fda-drugs-nda021883:v1</guid><description>The official Drugs@FDA dataset lists original submission 1 for NDA 021883 with status AP dated 2014-05-23, and names dalbavancin hydrochloride among the application record&apos;s active ingredients. Site addition: 2026-11-17. Source date: Cited source date 2014-05-23. Source checked: 2026-11-17. Limits: This is a selected source-linked record. Its source date and collection date stay separate; inclusion does not establish that the source is current, complete, safe, or effective. Sources: Drugs@FDA application NDA021883 · original submission status AP · 2014-05-23 · dataset 2026-11-16 (https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA021883%22&amp;limit=1)</description><dc:date>2026-11-17</dc:date><category>Source record added</category><category>dalbavancin</category></item><item><title>Drugs@FDA application NDA202714</title><link>https://peptidescanner.com/stories/fda-drugs-nda202714/</link><guid isPermaLink="false">peptidescanner:whats-new:source-record:fda-drugs-nda202714:v1</guid><description>The official Drugs@FDA dataset lists original submission 1 for NDA 202714 with status AP dated 2012-07-20, and names carfilzomib among the application record&apos;s active ingredients. Site addition: 2026-11-17. Source date: Cited source date 2012-07-20. Source checked: 2026-11-17. Limits: This is a selected source-linked record. Its source date and collection date stay separate; inclusion does not establish that the source is current, complete, safe, or effective. Sources: Drugs@FDA application NDA202714 · original submission status AP · 2012-07-20 · dataset 2026-11-16 (https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA202714%22&amp;limit=1)</description><dc:date>2026-11-17</dc:date><category>Source record added</category><category>carfilzomib</category></item><item><title>Drugs@FDA application NDA202799</title><link>https://peptidescanner.com/stories/fda-drugs-nda202799/</link><guid isPermaLink="false">peptidescanner:whats-new:source-record:fda-drugs-nda202799:v1</guid><description>The official Drugs@FDA dataset lists original submission 1 for NDA 202799 with status AP dated 2012-03-27, and names peginesatide acetate among the application record&apos;s active ingredients. Site addition: 2026-11-17. Source date: Cited source date 2012-03-27. Source checked: 2026-11-17. Limits: This is a selected source-linked record. Its source date and collection date stay separate; inclusion does not establish that the source is current, complete, safe, or effective. Sources: Drugs@FDA application NDA202799 · original submission status AP · 2012-03-27 · dataset 2026-11-16 (https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA202799%22&amp;limit=1)</description><dc:date>2026-11-17</dc:date><category>Source record added</category><category>peginesatide</category></item><item><title>Drugs@FDA application NDA208547</title><link>https://peptidescanner.com/stories/fda-drugs-nda208547/</link><guid isPermaLink="false">peptidescanner:whats-new:source-record:fda-drugs-nda208547:v1</guid><description>The official Drugs@FDA dataset lists original submission 1 for NDA 208547 with status AP dated 2016-06-01, and names gallium dotatate ga-68 among the application record&apos;s active ingredients. Site addition: 2026-11-17. Source date: Cited source date 2016-06-01. Source checked: 2026-11-17. Limits: This is a selected source-linked record. Its source date and collection date stay separate; inclusion does not establish that the source is current, complete, safe, or effective. Sources: Drugs@FDA application NDA208547 · original submission status AP · 2016-06-01 · dataset 2026-11-16 (https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA208547%22&amp;limit=1)</description><dc:date>2026-11-17</dc:date><category>Source record added</category><category>gallium-ga-68-dotatate</category></item><item><title>Drugs@FDA application NDA220934</title><link>https://peptidescanner.com/stories/fda-drugs-nda220934/</link><guid isPermaLink="false">peptidescanner:whats-new:source-record:fda-drugs-nda220934:v1</guid><description>The official Drugs@FDA dataset lists original submission 1 for NDA 220934 with status AP dated 2026-04-01, and names orforglipron calcium among the application record&apos;s active ingredients. Site addition: 2026-11-17. Source date: Cited source date 2026-04-01. Source checked: 2026-11-17. Limits: This is a selected source-linked record. Its source date and collection date stay separate; inclusion does not establish that the source is current, complete, safe, or effective. Sources: Drugs@FDA application NDA220934 · original submission status AP · 2026-04-01 · dataset 2026-11-16 (https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA220934%22&amp;limit=1)</description><dc:date>2026-11-17</dc:date><category>Source record added</category><category>orforglipron</category></item><item><title>Federal Register notice 2011-27327</title><link>https://peptidescanner.com/stories/federal-register-2011-27327/</link><guid isPermaLink="false">peptidescanner:whats-new:source-record:federal-register-2011-27327:v1</guid><description>The Federal Register published notice 2011-27327, attributed to FDA and its parent HHS department, on 2011-10-24. Its official title is “Oncologic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner&apos;s exact reviewed identity mapping connects the document to Peginesatide. Site addition: 2026-11-17. Source date: Cited source date 2011-10-24. Source checked: 2026-11-17. Limits: This is a selected source-linked record. Its source date and collection date stay separate; inclusion does not establish that the source is current, complete, safe, or effective. Sources: Federal Register notice 2011-27327 · published 2011-10-24 · Oncologic Drugs Advisory Committee; Notice of Meeting (https://www.govinfo.gov/content/pkg/FR-2011-10-24/pdf/2011-27327.pdf)</description><dc:date>2026-11-17</dc:date><category>Source record added</category><category>peginesatide</category></item><item><title>Federal Register notice 2012-10154</title><link>https://peptidescanner.com/stories/federal-register-2012-10154/</link><guid isPermaLink="false">peptidescanner:whats-new:source-record:federal-register-2012-10154:v1</guid><description>The Federal Register published notice 2012-10154, attributed to FDA and its parent HHS department, on 2012-04-27. Its official title is “Oncologic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner&apos;s exact reviewed identity mapping connects the document to Carfilzomib. Site addition: 2026-11-17. Source date: Cited source date 2012-04-27. Source checked: 2026-11-17. Limits: This is a selected source-linked record. Its source date and collection date stay separate; inclusion does not establish that the source is current, complete, safe, or effective. Sources: Federal Register notice 2012-10154 · published 2012-04-27 · Oncologic Drugs Advisory Committee; Notice of Meeting (https://www.govinfo.gov/content/pkg/FR-2012-04-27/pdf/2012-10154.pdf)</description><dc:date>2026-11-17</dc:date><category>Source record added</category><category>carfilzomib</category></item><item><title>Federal Register notice 2013-25588</title><link>https://peptidescanner.com/stories/federal-register-2013-25588/</link><guid isPermaLink="false">peptidescanner:whats-new:source-record:federal-register-2013-25588:v1</guid><description>The Federal Register published notice 2013-25588, attributed to FDA and its parent HHS department, on 2013-10-30. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner&apos;s exact reviewed identity mapping connects the document to Metreleptin. Site addition: 2026-11-17. Source date: Cited source date 2013-10-30. Source checked: 2026-11-17. Limits: This is a selected source-linked record. Its source date and collection date stay separate; inclusion does not establish that the source is current, complete, safe, or effective. Sources: Federal Register notice 2013-25588 · published 2013-10-30 · Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting (https://www.govinfo.gov/content/pkg/FR-2013-10-30/pdf/2013-25588.pdf)</description><dc:date>2026-11-17</dc:date><category>Source record added</category><category>metreleptin</category></item><item><title>Federal Register notice 2014-02942</title><link>https://peptidescanner.com/stories/federal-register-2014-02942/</link><guid isPermaLink="false">peptidescanner:whats-new:source-record:federal-register-2014-02942:v1</guid><description>The Federal Register published notice 2014-02942, attributed to FDA and its parent HHS department, on 2014-02-12. Its official title is “Anti-Infective Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner&apos;s exact reviewed identity mapping connects the document to Dalbavancin. Site addition: 2026-11-17. Source date: Cited source date 2014-02-12. Source checked: 2026-11-17. Limits: This is a selected source-linked record. Its source date and collection date stay separate; inclusion does not establish that the source is current, complete, safe, or effective. Sources: Federal Register notice 2014-02942 · published 2014-02-12 · Anti-Infective Drugs Advisory Committee; Notice of Meeting (https://www.govinfo.gov/content/pkg/FR-2014-02-12/pdf/2014-02942.pdf)</description><dc:date>2026-11-17</dc:date><category>Source record added</category><category>dalbavancin</category></item><item><title>Federal Register notice 2014-11175</title><link>https://peptidescanner.com/stories/federal-register-2014-11175/</link><guid isPermaLink="false">peptidescanner:whats-new:source-record:federal-register-2014-11175:v1</guid><description>The Federal Register published notice 2014-11175, attributed to FDA and its parent HHS department, on 2014-05-15. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; KYPROLIS,” and PeptideScanner&apos;s exact reviewed identity mapping connects the document to Carfilzomib. Site addition: 2026-11-17. Source date: Cited source date 2014-05-15. Source checked: 2026-11-17. Limits: This is a selected source-linked record. Its source date and collection date stay separate; inclusion does not establish that the source is current, complete, safe, or effective. Sources: Federal Register notice 2014-11175 · published 2014-05-15 · Determination of Regulatory Review Period for Purposes of Patent Extension; KYPROLIS (https://www.govinfo.gov/content/pkg/FR-2014-05-15/pdf/2014-11175.pdf)</description><dc:date>2026-11-17</dc:date><category>Source record added</category><category>carfilzomib</category></item><item><title>Federal Register notice 2014-11523</title><link>https://peptidescanner.com/stories/federal-register-2014-11523/</link><guid isPermaLink="false">peptidescanner:whats-new:source-record:federal-register-2014-11523:v1</guid><description>The Federal Register published notice 2014-11523, attributed to FDA and its parent HHS department, on 2014-05-20. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; OMONTYS,” and PeptideScanner&apos;s exact reviewed identity mapping connects the document to Peginesatide. Site addition: 2026-11-17. Source date: Cited source date 2014-05-20. Source checked: 2026-11-17. Limits: This is a selected source-linked record. Its source date and collection date stay separate; inclusion does not establish that the source is current, complete, safe, or effective. Sources: Federal Register notice 2014-11523 · published 2014-05-20 · Determination of Regulatory Review Period for Purposes of Patent Extension; OMONTYS (https://www.govinfo.gov/content/pkg/FR-2014-05-20/pdf/2014-11523.pdf)</description><dc:date>2026-11-17</dc:date><category>Source record added</category><category>peginesatide</category></item><item><title>Federal Register notice 2016-08682</title><link>https://peptidescanner.com/stories/federal-register-2016-08682/</link><guid isPermaLink="false">peptidescanner:whats-new:source-record:federal-register-2016-08682:v1</guid><description>The Federal Register published notice 2016-08682, attributed to FDA and its parent HHS department, on 2016-04-15. Its official title is “Product-Specific Bioequivalence Recommendations; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner&apos;s exact reviewed identity mapping connects the document to Glatiramer. Site addition: 2026-11-17. Source date: Cited source date 2016-04-15. Source checked: 2026-11-17. Limits: This is a selected source-linked record. Its source date and collection date stay separate; inclusion does not establish that the source is current, complete, safe, or effective. Sources: Federal Register notice 2016-08682 · published 2016-04-15 · Product-Specific Bioequivalence Recommendations; Draft and Revised Draft Guidances for Industry; Availability (https://www.govinfo.gov/content/pkg/FR-2016-04-15/pdf/2016-08682.pdf)</description><dc:date>2026-11-17</dc:date><category>Source record added</category><category>glatiramer-acetate</category></item><item><title>Federal Register notice 2016-13797</title><link>https://peptidescanner.com/stories/federal-register-2016-13797/</link><guid isPermaLink="false">peptidescanner:whats-new:source-record:federal-register-2016-13797:v1</guid><description>The Federal Register published notice 2016-13797, attributed to FDA and its parent HHS department, on 2016-06-10. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; TANZEUM,” and PeptideScanner&apos;s exact reviewed identity mapping connects the document to Albiglutide. Site addition: 2026-11-17. Source date: Cited source date 2016-06-10. Source checked: 2026-11-17. Limits: This is a selected source-linked record. Its source date and collection date stay separate; inclusion does not establish that the source is current, complete, safe, or effective. Sources: Federal Register notice 2016-13797 · published 2016-06-10 · Determination of Regulatory Review Period for Purposes of Patent Extension; TANZEUM (https://www.govinfo.gov/content/pkg/FR-2016-06-10/pdf/2016-13797.pdf)</description><dc:date>2026-11-17</dc:date><category>Source record added</category><category>albiglutide</category></item><item><title>Federal Register notice 2016-22935</title><link>https://peptidescanner.com/stories/federal-register-2016-22935/</link><guid isPermaLink="false">peptidescanner:whats-new:source-record:federal-register-2016-22935:v1</guid><description>The Federal Register published notice 2016-22935, attributed to FDA and its parent HHS department, on 2016-09-23. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; MYALEPT,” and PeptideScanner&apos;s exact reviewed identity mapping connects the document to Metreleptin. Site addition: 2026-11-17. Source date: Cited source date 2016-09-23. Source checked: 2026-11-17. Limits: This is a selected source-linked record. Its source date and collection date stay separate; inclusion does not establish that the source is current, complete, safe, or effective. Sources: Federal Register notice 2016-22935 · published 2016-09-23 · Determination of Regulatory Review Period for Purposes of Patent Extension; MYALEPT (https://www.govinfo.gov/content/pkg/FR-2016-09-23/pdf/2016-22935.pdf)</description><dc:date>2026-11-17</dc:date><category>Source record added</category><category>metreleptin</category></item><item><title>Federal Register notice 2018-02768</title><link>https://peptidescanner.com/stories/federal-register-2018-02768/</link><guid isPermaLink="false">peptidescanner:whats-new:source-record:federal-register-2018-02768:v1</guid><description>The Federal Register published notice 2018-02768, attributed to FDA and its parent HHS department, on 2018-02-12. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; DALVANCE,” and PeptideScanner&apos;s exact reviewed identity mapping connects the document to Dalbavancin. Site addition: 2026-11-17. Source date: Cited source date 2018-02-12. Source checked: 2026-11-17. Limits: This is a selected source-linked record. Its source date and collection date stay separate; inclusion does not establish that the source is current, complete, safe, or effective. Sources: Federal Register notice 2018-02768 · published 2018-02-12 · Determination of Regulatory Review Period for Purposes of Patent Extension; DALVANCE (https://www.govinfo.gov/content/pkg/FR-2018-02-12/pdf/2018-02768.pdf)</description><dc:date>2026-11-17</dc:date><category>Source record added</category><category>dalbavancin</category></item><item><title>Federal Register notice 2018-15735</title><link>https://peptidescanner.com/stories/federal-register-2018-15735/</link><guid isPermaLink="false">peptidescanner:whats-new:source-record:federal-register-2018-15735:v1</guid><description>The Federal Register published notice 2018-15735, attributed to FDA and its parent HHS department, on 2018-07-23. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner&apos;s exact reviewed identity mapping connects the document to Glatiramer. Site addition: 2026-11-17. Source date: Cited source date 2018-07-23. Source checked: 2026-11-17. Limits: This is a selected source-linked record. Its source date and collection date stay separate; inclusion does not establish that the source is current, complete, safe, or effective. Sources: Federal Register notice 2018-15735 · published 2018-07-23 · Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability (https://www.govinfo.gov/content/pkg/FR-2018-07-23/pdf/2018-15735.pdf)</description><dc:date>2026-11-17</dc:date><category>Source record added</category><category>glatiramer-acetate</category></item><item><title>Federal Register notice 2019-02146</title><link>https://peptidescanner.com/stories/federal-register-2019-02146/</link><guid isPermaLink="false">peptidescanner:whats-new:source-record:federal-register-2019-02146:v1</guid><description>The Federal Register published notice 2019-02146, attributed to FDA and its parent HHS department, on 2019-02-13. Its official title is “Takeda Pharmaceuticals U.S.A., Inc.; Withdrawal of Approval of a New Drug Application for OMONTYS (peginesatide) Injection,” and PeptideScanner&apos;s exact reviewed identity mapping connects the document to Peginesatide. Site addition: 2026-11-17. Source date: Cited source date 2019-02-13. Source checked: 2026-11-17. Limits: This is a selected source-linked record. Its source date and collection date stay separate; inclusion does not establish that the source is current, complete, safe, or effective. Sources: Federal Register notice 2019-02146 · published 2019-02-13 · Takeda Pharmaceuticals U.S.A., Inc.; Withdrawal of Approval of a New Drug Application for OMONTYS (peginesatide) Injection (https://www.govinfo.gov/content/pkg/FR-2019-02-13/pdf/2019-02146.pdf)</description><dc:date>2026-11-17</dc:date><category>Source record added</category><category>peginesatide</category></item><item><title>Federal Register notice 2019-09007</title><link>https://peptidescanner.com/stories/federal-register-2019-09007/</link><guid isPermaLink="false">peptidescanner:whats-new:source-record:federal-register-2019-09007:v1</guid><description>The Federal Register published notice 2019-09007, attributed to FDA and its parent HHS department, on 2019-05-03. Its official title is “21st Century Cures Act: Annual Compilation of Notices of Updates From the Susceptibility Test Interpretive Criteria Web Page; Request for Comments,” and PeptideScanner&apos;s exact reviewed identity mapping connects the document to Dalbavancin. Site addition: 2026-11-17. Source date: Cited source date 2019-05-03. Source checked: 2026-11-17. Limits: This is a selected source-linked record. Its source date and collection date stay separate; inclusion does not establish that the source is current, complete, safe, or effective. Sources: Federal Register notice 2019-09007 · published 2019-05-03 · 21st Century Cures Act: Annual Compilation of Notices of Updates From the Susceptibility Test Interpretive Criteria Web Page; Request for Comments (https://www.govinfo.gov/content/pkg/FR-2019-05-03/pdf/2019-09007.pdf)</description><dc:date>2026-11-17</dc:date><category>Source record added</category><category>dalbavancin</category></item><item><title>Federal Register notice 2026-15149</title><link>https://peptidescanner.com/stories/federal-register-2026-15149/</link><guid isPermaLink="false">peptidescanner:whats-new:source-record:federal-register-2026-15149:v1</guid><description>The Federal Register published notice 2026-15149, attributed to FDA and its parent HHS department, on 2026-07-28. Its official title is “Pediatric Advisory Committee (PAC); Notice of Meeting; Establishment of a Public Docket; Request for Comments,” and PeptideScanner&apos;s exact reviewed identity mapping connects the document to Dalbavancin. Site addition: 2026-11-17. Source date: Cited source date 2026-07-28. Source checked: 2026-11-17. Limits: This is a selected source-linked record. Its source date and collection date stay separate; inclusion does not establish that the source is current, complete, safe, or effective. Sources: Federal Register notice 2026-15149 · published 2026-07-28 · Pediatric Advisory Committee (PAC); Notice of Meeting; Establishment of a Public Docket; Request for Comments (https://www.govinfo.gov/content/pkg/FR-2026-07-28/pdf/2026-15149.pdf)</description><dc:date>2026-11-17</dc:date><category>Source record added</category><category>dalbavancin</category></item><item><title>Federal Register notice 97-10541</title><link>https://peptidescanner.com/stories/federal-register-97-10541/</link><guid isPermaLink="false">peptidescanner:whats-new:source-record:federal-register-97-10541:v1</guid><description>The Federal Register published notice 97-10541, attributed to FDA and its parent HHS department, on 1997-04-23. Its official title is “Advisory Committee; Notice of Meeting,” and PeptideScanner&apos;s exact reviewed identity mapping connects the document to Mecasermin. Site addition: 2026-11-17. Source date: Cited source date 1997-04-23. Source checked: 2026-11-17. Limits: This is a selected source-linked record. Its source date and collection date stay separate; inclusion does not establish that the source is current, complete, safe, or effective. Sources: Federal Register notice 97-10541 · published 1997-04-23 · Advisory Committee; Notice of Meeting (https://www.govinfo.gov/content/pkg/FR-1997-04-23/pdf/97-10541.pdf)</description><dc:date>2026-11-17</dc:date><category>Source record added</category><category>mecasermin</category></item><item><title>Federal Register notice 98-7053</title><link>https://peptidescanner.com/stories/federal-register-98-7053/</link><guid isPermaLink="false">peptidescanner:whats-new:source-record:federal-register-98-7053:v1</guid><description>The Federal Register published notice 98-7053, attributed to FDA and its parent HHS department, on 1998-03-19. Its official title is “Peripheral and Central Nervous System Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner&apos;s exact reviewed identity mapping connects the document to Mecasermin. Site addition: 2026-11-17. Source date: Cited source date 1998-03-19. Source checked: 2026-11-17. Limits: This is a selected source-linked record. Its source date and collection date stay separate; inclusion does not establish that the source is current, complete, safe, or effective. Sources: Federal Register notice 98-7053 · published 1998-03-19 · Peripheral and Central Nervous System Drugs Advisory Committee; Notice of Meeting (https://www.govinfo.gov/content/pkg/FR-1998-03-19/pdf/98-7053.pdf)</description><dc:date>2026-11-17</dc:date><category>Source record added</category><category>mecasermin</category></item><item><title>Federal Register notice E6-12571</title><link>https://peptidescanner.com/stories/federal-register-e6-12571/</link><guid isPermaLink="false">peptidescanner:whats-new:source-record:federal-register-e6-12571:v1</guid><description>The Federal Register published notice E6-12571, attributed to FDA and its parent HHS department, on 2006-08-03. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; IPLEX,” and PeptideScanner&apos;s exact reviewed identity mapping connects the document to Mecasermin. Site addition: 2026-11-17. Source date: Cited source date 2006-08-03. Source checked: 2026-11-17. Limits: This is a selected source-linked record. Its source date and collection date stay separate; inclusion does not establish that the source is current, complete, safe, or effective. Sources: Federal Register notice E6-12571 · published 2006-08-03 · Determination of Regulatory Review Period for Purposes of Patent Extension; IPLEX (https://www.govinfo.gov/content/pkg/FR-2006-08-03/pdf/E6-12571.pdf)</description><dc:date>2026-11-17</dc:date><category>Source record added</category><category>mecasermin</category></item><item><title>Federal Register notice E6-9138</title><link>https://peptidescanner.com/stories/federal-register-e6-9138/</link><guid isPermaLink="false">peptidescanner:whats-new:source-record:federal-register-e6-9138:v1</guid><description>The Federal Register published notice E6-9138, attributed to FDA and its parent HHS department, on 2006-06-13. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; INCRELEX,” and PeptideScanner&apos;s exact reviewed identity mapping connects the document to Mecasermin. Site addition: 2026-11-17. Source date: Cited source date 2006-06-13. Source checked: 2026-11-17. Limits: This is a selected source-linked record. Its source date and collection date stay separate; inclusion does not establish that the source is current, complete, safe, or effective. Sources: Federal Register notice E6-9138 · published 2006-06-13 · Determination of Regulatory Review Period for Purposes of Patent Extension; INCRELEX (https://www.govinfo.gov/content/pkg/FR-2006-06-13/pdf/E6-9138.pdf)</description><dc:date>2026-11-17</dc:date><category>Source record added</category><category>mecasermin</category></item><item><title>Federal Register proposed rule 2015-32246</title><link>https://peptidescanner.com/stories/federal-register-2015-32246/</link><guid isPermaLink="false">peptidescanner:whats-new:source-record:federal-register-2015-32246:v1</guid><description>The Federal Register published proposed rule 2015-32246, attributed to FDA and its parent HHS department, on 2015-12-23. Its official title is “Fixed-Combination and Co-Packaged Drugs: Applications for Approval and Combinations of Active Ingredients Under Consideration for Inclusion in an Over-the-Counter Monograph,” and PeptideScanner&apos;s exact reviewed identity mapping connects the document to Glatiramer. Site addition: 2026-11-17. Source date: Cited source date 2015-12-23. Source checked: 2026-11-17. Limits: This is a selected source-linked record. Its source date and collection date stay separate; inclusion does not establish that the source is current, complete, safe, or effective. Sources: Federal Register proposed rule 2015-32246 · published 2015-12-23 · Fixed-Combination and Co-Packaged Drugs: Applications for Approval and Combinations of Active Ingredients Under Consideration for Inclusion in an Over-the-Counter Monograph (https://www.govinfo.gov/content/pkg/FR-2015-12-23/pdf/2015-32246.pdf)</description><dc:date>2026-11-17</dc:date><category>Source record added</category><category>glatiramer-acetate</category></item><item><title>Longitudinal Serum and Cerebrospinal Fluid S100B Concentrations After Aneurysmal Subarachnoid Hemorrhage: An Exploratory Comparison of Historical Cohorts With and Without Cerebrolysin Exposure.</title><link>https://peptidescanner.com/stories/pubmed-pmid-43030876-cerebrolysin/</link><guid isPermaLink="false">peptidescanner:whats-new:source-record:pubmed-pmid-43030876-cerebrolysin:v1</guid><description>PubMed lists PMID 43030876 in Journal of clinical medicine as Journal Article, with publication-date metadata of 2026-11-09 (day precision). PeptideScanner associated the retained record with the identity slug cerebrolysin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article&apos;s findings. Site addition: 2026-11-17. Source date: Cited source date 2026-11-14. Source checked: 2026-11-17. Limits: This is a selected source-linked record. Its source date and collection date stay separate; inclusion does not establish that the source is current, complete, safe, or effective. Sources: Longitudinal Serum and Cerebrospinal Fluid S100B Concentrations After Aneurysmal Subarachnoid Hemorrhage: An Exploratory Comparison of Historical Cohorts With and Without Cerebrolysin Exposure. · retained source version 1:2026-11-14:current:6a0f889ab8890d1cbbef3a1aab9a889de06ca252cacd6c267bdb3ab7abb6c7cf (https://pubmed.ncbi.nlm.nih.gov/43030876/)</description><dc:date>2026-11-17</dc:date><category>Source record added</category><category>cerebrolysin</category></item><item><title>Insulin glargine-aldy profile</title><link>https://peptidescanner.com/peptides/insulin-glargine-aldy/</link><guid isPermaLink="false">peptidescanner:whats-new:profile:insulin-glargine-aldy:v4</guid><description>A long-acting insulin glargine product licensed by FDA as Langlara in April 2026 to improve blood-sugar control in adults and children with diabetes. Profile updated: We now state that the label calls Langlara biosimilar to Lantus, and that the trials in its label are the reference product’s trials, which the Lantus label describes as trials of Lantus. We also no longer suggest that an unread page of the approval letter might hold FDA’s findings: it does not. Site addition: 2026-11-16. Source checked: 2026-11-16. Limits: A source-linked profile account preserves the cited scope; it is not a complete review, treatment recommendation, or medical advice. Sources: Drugs@FDA application BLA761412 · original submission status AP · 2026-04-29 · dataset 2026-08-13 (https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22BLA761412%22&amp;limit=1); LANGLARA (insulin glargine-aldy) injection, solution · SPL version 5 · published 2026-07-08 (https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&amp;setid=5328761e-59d3-ca7a-e063-6394a90ae810&amp;version=5); Langlara (insulin glargine-aldy): BLA 761412 approval letter, April 29, 2026 (https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/761412Orig1s000ltr.pdf); Lantus (insulin glargine) prescribing information, application 021081 supplements S-078 and S-079, revised June 2023 (https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021081s078s079lbl.pdf)</description><dc:date>2026-11-16</dc:date><category>Profile updated</category><category>insulin-glargine-aldy</category></item><item><title>Octreotide profile</title><link>https://peptidescanner.com/peptides/octreotide/</link><guid isPermaLink="false">peptidescanner:whats-new:profile:octreotide:v4</guid><description>A somatostatin analogue first approved by FDA as Sandostatin in 1988, used for acromegaly and for diarrhea and flushing caused by certain hormone-secreting tumors. Profile updated: We added the FDA labels of Sandostatin LAR and Mycapssa and now describe each trial with the octreotide product it tested, because the generic label cited on this page has no clinical studies section. Site addition: 2026-11-16. Source checked: 2026-11-16. Limits: A source-linked profile account preserves the cited scope; it is not a complete review, treatment recommendation, or medical advice. Sources: Drugs@FDA application NDA019667 · original submission status AP · 1988-10-21 · dataset 2026-08-13 (https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA019667%22&amp;limit=1); Drugs@FDA application NDA021008 · original submission status AP · 1998-11-25 · dataset 2026-08-13 (https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA021008%22&amp;limit=1); Drugs@FDA application NDA208232 · original submission status AP · 2020-06-26 · dataset 2026-08-13 (https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA208232%22&amp;limit=1); Drugs@FDA application NDA213224 · original submission status AP · 2024-09-27 · dataset 2026-08-13 (https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA213224%22&amp;limit=1); Octreotide acetate injection, solution · SPL version 2 · published 2026-02-02 (https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&amp;setid=387d7f8d-9762-4f6b-99e1-bdc50b8a1633&amp;version=2); Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial (MPOWERED, 2022) · PMID 34953531 (https://doi.org/10.1016/S2213-8587(21)00296-5); Short term treatment of acromegaly with the somatostatin analog octreotide: the first double-blind randomized placebo-controlled study on its effects (1990) · PMID 2229278 (https://doi.org/10.1210/jcem-71-5-1189); Sandostatin LAR Depot (octreotide acetate) prescribing information, NDA 021008 supplement S-049, revised July 2024 (https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/021008s049lbl.pdf); Mycapssa (octreotide) prescribing information, NDA 208232 supplement S-006, revised July 2024 (https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208232s006lbl.pdf)</description><dc:date>2026-11-16</dc:date><category>Profile updated</category><category>octreotide</category></item><item><title>Petrelintide profile</title><link>https://peptidescanner.com/peptides/petrelintide/</link><guid isPermaLink="false">peptidescanner:whats-new:profile:petrelintide:v4</guid><description>An experimental amylin analogue from Zealand Pharma and Roche, in Phase 3 trials. It is not FDA-approved. Profile updated: We added the published results of the ZUPREME 1 Phase 2 trial and two more ClinicalTrials.gov records. Earlier versions said the only published human results were from Phase 1 trials. Site addition: 2026-11-16. Source checked: 2026-11-16. Limits: A source-linked profile account preserves the cited scope; it is not a complete review, treatment recommendation, or medical advice. Sources: ClinicalTrials.gov record NCT06662539 · retained source version 2026-03-23:25a9d8533efb66766440e5abf5b03342f70235dae33ae71a773e757bb8847402 (https://clinicaltrials.gov/study/NCT06662539); ClinicalTrials.gov record NCT06926842 · retained source version 2026-09-09:66566db76c0ba35707f571957d43a26bb1a34c1cb277263d2109ca1fdebaf137 (https://clinicaltrials.gov/study/NCT06926842); ClinicalTrials.gov record NCT07076030 · retained source version 2026-01-28:68a10be352b494ee43c532b4782a5eda7e3dc609ba1c5da1829378a353712497 (https://clinicaltrials.gov/study/NCT07076030); Petrelintide With Enicepatide in Adults With Obesity or Overweight · record history version 3 · last update posted 2026-07-07 (https://clinicaltrials.gov/study/NCT07589686?a=3&amp;tab=history); ClinicalTrials.gov record NCT07843472 · retained source version 2026-10-07:b4d7f3eecf4b6c9a8842198319f5d5c3a421bf03ca09434d4d315fdacfc97697 (https://clinicaltrials.gov/study/NCT07843472); ClinicalTrials.gov record NCT07843485 · retained source version 2026-11-05:e5fd0540362d59efc4e0e476ab3f05c74427735d5576cee67cbafed4c6f394d5 (https://clinicaltrials.gov/study/NCT07843485); ClinicalTrials.gov record NCT07843498 · retained source version 2026-11-05:9b532d149aaffed6b38bd85ef1731c2342003d62a19554586ffc692016cb1e62 (https://clinicaltrials.gov/study/NCT07843498); Petrelintide, a human amylin analogue for the treatment of obesity (ZUPREME 1): a randomised, double-blind, placebo-controlled, phase 2 trial (2026) · PMID 42810355 (https://doi.org/10.1016/S2213-8587(26)00213-5); Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Petrelintide for Weight Management: Two Randomized, Controlled Phase 1 Trials (2026) · PMID 42017294 (https://doi.org/10.1111/dom.70753)</description><dc:date>2026-11-16</dc:date><category>Profile updated</category><category>petrelintide</category></item><item><title>GHRP-2 profile</title><link>https://peptidescanner.com/peptides/ghrp-2/</link><guid isPermaLink="false">peptidescanner:whats-new:profile:ghrp-2:v2</guid><description>A synthetic six-amino-acid growth hormone secretagogue, also called pralmorelin, that FDA lists among compounding substances that may present significant safety risks. Profile updated: We added FDA’s May 2026 503A nominations list, which places GHRP-2 in category 3, and two human studies of its effect on growth hormone and appetite and its use as a diagnostic test. Site addition: 2026-11-16. Source checked: 2026-11-16. Limits: A source-linked profile account preserves the cited scope; it is not a complete review, treatment recommendation, or medical advice. Sources: Obese subjects respond to the stimulatory effect of the ghrelin agonist growth hormone-releasing peptide-2 on food intake (2006) · PMID 16861611 (https://doi.org/10.1038/oby.2006.121); A simple diagnostic test using GH-releasing peptide-2 in adult GH deficiency (2007) · PMID 17609397 (https://doi.org/10.1530/EJE-07-0066); Pralmorelin (GHRP-2) substance identity record (https://precision.fda.gov/uniisearch/srs/unii/E6S6E1F19M); Certain bulk drug substances for use in compounding that may present significant safety risks (https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks); Bulk drug substances nominated for use in compounding under section 503A (categories 1 to 3) · updated May 14, 2026 (https://www.fda.gov/media/94155/download); Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 (https://www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances); HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) (https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf)</description><dc:date>2026-11-16</dc:date><category>Profile updated</category><category>ghrp-2</category></item><item><title>LL-37 profile</title><link>https://peptidescanner.com/peptides/ll-37/</link><guid isPermaLink="false">peptidescanner:whats-new:profile:ll-37:v2</guid><description>A 37-amino-acid human cathelicidin peptide, also called ropocamptide, tested in small trials in chronic ulcers. FDA lists it among compounding substances that may present significant safety risks. Profile updated: We added three randomized trials of LL-37 in chronic ulcers, FDA’s advisory committee page listing LL-37 for a meeting before the end of February 2027, and the spelling LL37 that trial registrations use, so that those registrations are matched. Site addition: 2026-11-16. Source checked: 2026-11-16. Limits: A source-linked profile account preserves the cited scope; it is not a complete review, treatment recommendation, or medical advice. Sources: ClinicalTrials.gov record NCT02225366 · retained source version 2021-12-09:d146b413ecf538257bf7086de94ac2024ae7cdada6f1e2c17c5051fba93f7d5c (https://clinicaltrials.gov/study/NCT02225366); Efficacy of LL-37 cream in enhancing healing of diabetic foot ulcer: a randomized double-blind controlled trial (2023) · PMID 37480520 (https://doi.org/10.1007/s00403-023-02657-8); Treatment with LL-37 is safe and effective in enhancing healing of hard-to-heal venous leg ulcers: a randomized, placebo-controlled clinical trial (2014) · PMID 25041740 (https://doi.org/10.1111/wrr.12211); Evaluation of LL-37 in healing of hard-to-heal venous leg ulcers: A multicentric prospective randomized placebo-controlled clinical trial (2021) · PMID 34687253 (https://doi.org/10.1111/wrr.12977); Ropocamptide (cathelicidin LL-37, human) substance identity record (https://precision.fda.gov/uniisearch/srs/unii/3DD771JO2H); Meeting of the Pharmacy Compounding Advisory Committee (before the end of February 2027) · content current as of April 15, 2026 (https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/meeting-pharmacy-compounding-advisory-committee); Certain bulk drug substances for use in compounding that may present significant safety risks (https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks); Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 (https://www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances); HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) (https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf)</description><dc:date>2026-11-16</dc:date><category>Profile updated</category><category>ll-37</category></item><item><title>Melanotan II profile</title><link>https://peptidescanner.com/peptides/melanotan-ii/</link><guid isPermaLink="false">peptidescanner:whats-new:profile:melanotan-ii:v2</guid><description>A synthetic cyclic seven-unit peptide that FDA lists among compounding substances that may present significant safety risks, citing case reports of serious adverse events. Profile updated: We added two early human studies of Melanotan II and FDA’s advisory committee page listing it for a meeting before the end of February 2027. Site addition: 2026-11-16. Source checked: 2026-11-16. Limits: A source-linked profile account preserves the cited scope; it is not a complete review, treatment recommendation, or medical advice. Sources: Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study (1996) · PMID 8637402 (https://doi.org/10.1016/0024-3205(96)00160-9); Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction (2000) · PMID 11018622 (https://doi.org/10.1016/s0090-4295(00)00680-4); Melanotan II substance identity record (https://precision.fda.gov/uniisearch/srs/unii/UPF5CJ93X7); Meeting of the Pharmacy Compounding Advisory Committee (before the end of February 2027) · content current as of April 15, 2026 (https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/meeting-pharmacy-compounding-advisory-committee); Certain bulk drug substances for use in compounding that may present significant safety risks (https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks); Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 (https://www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances); HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) (https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf)</description><dc:date>2026-11-16</dc:date><category>Profile updated</category><category>melanotan-ii</category></item><item><title>Selank profile</title><link>https://peptidescanner.com/peptides/selank/</link><guid isPermaLink="false">peptidescanner:whats-new:profile:selank:v2</guid><description>A synthetic seven-amino-acid peptide that FDA lists among withdrawn compounding nominations with possible safety risks. FDA states that it lacks important information on its safety in people. Profile updated: We added a 2015 Russian clinical study of selank added to phenazepam in patients with anxiety disorders. Earlier versions said no human study was cited among the sources reviewed. Site addition: 2026-11-16. Source checked: 2026-11-16. Limits: A source-linked profile account preserves the cited scope; it is not a complete review, treatment recommendation, or medical advice. Sources: Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats (2017) · PMID 28280289 (https://doi.org/10.1155/2017/5091027); Optimization of the treatment of anxiety disorders with selank (2015, in Russian) · PMID 26356395 (https://doi.org/10.17116/jnevro20151156133-40); Selank substance identity record (https://precision.fda.gov/uniisearch/srs/unii/TS9JR8EP1G); Certain bulk drug substances for use in compounding that may present significant safety risks (https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks); Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 (https://www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances); HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) (https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf)</description><dc:date>2026-11-16</dc:date><category>Profile updated</category><category>selank</category></item><item><title>5-Amino-1MQ profile</title><link>https://peptidescanner.com/peptides/5-amino-1mq/</link><guid isPermaLink="false">peptidescanner:whats-new:profile:5-amino-1mq:v1</guid><description>A small synthetic compound, not a peptide, that blocks the enzyme NNMT. A 2018 study found that obese mice given it lost weight; no human studies are reported. Site addition: 2026-11-16. Source checked: 2026-11-16. Limits: A source-linked profile account preserves the cited scope; it is not a complete review, treatment recommendation, or medical advice. Sources: Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice (2018) · PMID 29155147 (https://doi.org/10.1016/j.bcp.2017.11.007); 5-Amino-1-methylquinolinium substance identity record (https://precision.fda.gov/uniisearch/srs/unii/PMX593N4N3); Certain bulk drug substances for use in compounding that may present significant safety risks (https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks); Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 (https://www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances); HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) (https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf)</description><dc:date>2026-11-16</dc:date><category>Profile published</category><category>5-amino-1mq</category></item><item><title>Albiglutide profile</title><link>https://peptidescanner.com/peptides/albiglutide/</link><guid isPermaLink="false">peptidescanner:whats-new:profile:albiglutide:v1</guid><description>A GLP-1 receptor agonist made by fusing GLP-1 analogue peptides to human albumin. FDA approved it as Tanzeum in 2014, and Drugs@FDA lists it as discontinued. Site addition: 2026-11-16. Source checked: 2026-11-16. Limits: A source-linked profile account preserves the cited scope; it is not a complete review, treatment recommendation, or medical advice. Sources: Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial (2018) · PMID 30291013 (https://doi.org/10.1016/S0140-6736(18)32261-X); Albiglutide substance identity record (https://precision.fda.gov/uniisearch/srs/unii/5E7U48495E); Drugs@FDA: TANZEUM (albiglutide), application 125431 · original approval April 15, 2014 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=125431); Certain bulk drug substances for use in compounding that may present significant safety risks (https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks); Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 (https://www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances); HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) (https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf)</description><dc:date>2026-11-16</dc:date><category>Profile published</category><category>albiglutide</category></item><item><title>Carfilzomib profile</title><link>https://peptidescanner.com/peptides/carfilzomib/</link><guid isPermaLink="false">peptidescanner:whats-new:profile:carfilzomib:v1</guid><description>A tetrapeptide epoxyketone proteasome inhibitor approved by FDA in 2012 as Kyprolis for relapsed or refractory multiple myeloma. Site addition: 2026-11-16. Source checked: 2026-11-16. Limits: A source-linked profile account preserves the cited scope; it is not a complete review, treatment recommendation, or medical advice. Sources: KYPROLIS (carfilzomib) for injection · SPL version 59 · published 2025-06-26 (https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&amp;setid=ea66eb30-e665-4693-99a1-a9d3b4bbe2d6&amp;version=59); Drugs@FDA: KYPROLIS (carfilzomib), NDA 202714 · original approval July 20, 2012 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=202714)</description><dc:date>2026-11-16</dc:date><category>Profile published</category><category>carfilzomib</category></item><item><title>Cerebrolysin profile</title><link>https://peptidescanner.com/peptides/cerebrolysin/</link><guid isPermaLink="false">peptidescanner:whats-new:profile:cerebrolysin:v1</guid><description>A mixture of small peptides and amino acids from pig brain, used for stroke in several countries. A 2023 Cochrane review found it probably does not reduce deaths, and no FDA approval is reported. Site addition: 2026-11-16. Source checked: 2026-11-16. Limits: A source-linked profile account preserves the cited scope; it is not a complete review, treatment recommendation, or medical advice. Sources: Cerebrolysin for acute ischaemic stroke (2023) · PMID 37818733 (https://doi.org/10.1002/14651858.CD007026.pub7); Cerebrolysin substance identity record (https://precision.fda.gov/uniisearch/srs/unii/37KZM6S21G); Certain bulk drug substances for use in compounding that may present significant safety risks (https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks); Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 (https://www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances); HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) (https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf)</description><dc:date>2026-11-16</dc:date><category>Profile published</category><category>cerebrolysin</category></item><item><title>Dalbavancin profile</title><link>https://peptidescanner.com/peptides/dalbavancin/</link><guid isPermaLink="false">peptidescanner:whats-new:profile:dalbavancin:v1</guid><description>A lipoglycopeptide antibiotic approved by FDA in 2014 as Dalvance for acute bacterial skin and skin structure infections caused by susceptible Gram-positive bacteria, including MRSA. Site addition: 2026-11-16. Source checked: 2026-11-16. Limits: A source-linked profile account preserves the cited scope; it is not a complete review, treatment recommendation, or medical advice. Sources: DALVANCE (dalbavancin) for injection · SPL version 29 · published 2025-11-17 (https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&amp;setid=4b4674d8-4d1e-4728-8465-d42ada33fa5c&amp;version=29); Drugs@FDA: DALVANCE (dalbavancin hydrochloride), NDA 021883 · original approval May 23, 2014 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=021883)</description><dc:date>2026-11-16</dc:date><category>Profile published</category><category>dalbavancin</category></item><item><title>Dihexa profile</title><link>https://peptidescanner.com/peptides/dihexa/</link><guid isPermaLink="false">peptidescanner:whats-new:profile:dihexa:v1</guid><description>A lab-made, stabilized fragment of the hormone angiotensin IV, designed as a possible dementia drug and tested in rats. FDA has identified no human exposure data, and no FDA approval is reported. Site addition: 2026-11-16. Source checked: 2026-11-16. Limits: A source-linked profile account preserves the cited scope; it is not a complete review, treatment recommendation, or medical advice. Sources: Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents (2013) · PMID 23055539 (https://doi.org/10.1124/jpet.112.199497); The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor/c-met system (2014) · PMID 25187433 (https://doi.org/10.1124/jpet.114.218735); Dihexa substance identity record (https://precision.fda.gov/uniisearch/srs/unii/9WYX65A5C2); Certain bulk drug substances for use in compounding that may present significant safety risks (https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks); Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 (https://www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances); HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) (https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf)</description><dc:date>2026-11-16</dc:date><category>Profile published</category><category>dihexa</category></item><item><title>Efinopegdutide profile</title><link>https://peptidescanner.com/peptides/efinopegdutide/</link><guid isPermaLink="false">peptidescanner:whats-new:profile:efinopegdutide:v1</guid><description>An experimental GLP-1 and glucagon receptor agonist studied for fatty liver disease. In a 24-week trial it reduced liver fat more than semaglutide; no FDA approval is reported. Site addition: 2026-11-16. Source checked: 2026-11-16. Limits: A source-linked profile account preserves the cited scope; it is not a complete review, treatment recommendation, or medical advice. Sources: A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease (2023) · PMID 37355043 (https://doi.org/10.1016/j.jhep.2023.05.013); Efinopegdutide substance identity record (https://precision.fda.gov/uniisearch/srs/unii/DR6P1M58PO); Certain bulk drug substances for use in compounding that may present significant safety risks (https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks); Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 (https://www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances); HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) (https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf)</description><dc:date>2026-11-16</dc:date><category>Profile published</category><category>efinopegdutide</category></item><item><title>Efpeglenatide profile</title><link>https://peptidescanner.com/peptides/efpeglenatide/</link><guid isPermaLink="false">peptidescanner:whats-new:profile:efpeglenatide:v1</guid><description>A GLP-1 receptor agonist made by joining an exendin-4 analogue to an antibody fragment. A 4,076-person trial found fewer cardiovascular events than placebo; no FDA approval is reported. Site addition: 2026-11-16. Source checked: 2026-11-16. Limits: A source-linked profile account preserves the cited scope; it is not a complete review, treatment recommendation, or medical advice. Sources: ClinicalTrials.gov record NCT07379333 · retained source version 2026-05-13:c599578eaa8d429e0152e13caf981fed9266ac8441a80524f20f68e1f1aaac63 (https://clinicaltrials.gov/study/NCT07379333); Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes (2021) · PMID 34215025 (https://doi.org/10.1056/NEJMoa2108269); Efpeglenatide substance identity record (https://precision.fda.gov/uniisearch/srs/unii/3M1V5Z2270); Certain bulk drug substances for use in compounding that may present significant safety risks (https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks); Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 (https://www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances); HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) (https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf)</description><dc:date>2026-11-16</dc:date><category>Profile published</category><category>efpeglenatide</category></item><item><title>Follistatin-344 profile</title><link>https://peptidescanner.com/peptides/follistatin-344/</link><guid isPermaLink="false">peptidescanner:whats-new:profile:follistatin-344:v1</guid><description>A form of follistatin, a natural protein, not a peptide, that blocks the muscle-limiting signal myostatin. Small gene-therapy trials have tested its gene; no FDA approval is reported. Site addition: 2026-11-16. Source checked: 2026-11-16. Limits: A source-linked profile account preserves the cited scope; it is not a complete review, treatment recommendation, or medical advice. Sources: Detection of black market follistatin 344 (2019) · PMID 31758732 (https://doi.org/10.1002/dta.2741); Follistatin gene therapy for sporadic inclusion body myositis improves functional outcomes (2017) · PMID 28279643 (https://doi.org/10.1016/j.ymthe.2017.02.015); A phase 1/2a follistatin gene therapy trial for Becker muscular dystrophy (2015) · PMID 25322757 (https://doi.org/10.1038/mt.2014.200); Follistatin (activin-binding protein) substance identity record (https://precision.fda.gov/uniisearch/srs/unii/506IY26H2I); Certain bulk drug substances for use in compounding that may present significant safety risks (https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks); Definition of the Term “Biological Product” (final rule, February 21, 2020) · FR Doc. 2020-03505 (https://www.federalregister.gov/documents/2020/02/21/2020-03505/definition-of-the-term-biological-product); Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 (https://www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances); HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) (https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf)</description><dc:date>2026-11-16</dc:date><category>Profile published</category><category>follistatin-344</category></item><item><title>FOXO4-DRI profile</title><link>https://peptidescanner.com/peptides/foxo4-dri/</link><guid isPermaLink="false">peptidescanner:whats-new:profile:foxo4-dri:v1</guid><description>A lab-designed peptide that makes ageing (senescent) cells die by blocking FOXO4 from holding p53. It restored some functions in old mice; no human studies and no FDA approval are reported. Site addition: 2026-11-16. Source checked: 2026-11-16. Limits: A source-linked profile account preserves the cited scope; it is not a complete review, treatment recommendation, or medical advice. Sources: Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging (2017) · PMID 28340339 (https://doi.org/10.1016/j.cell.2017.02.031); FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice (2020) · PMID 31959736 (https://doi.org/10.18632/aging.102682); Certain bulk drug substances for use in compounding that may present significant safety risks (https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks); Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 (https://www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances); HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) (https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf)</description><dc:date>2026-11-16</dc:date><category>Profile published</category><category>foxo4-dri</category></item><item><title>Gallium Ga 68 dotatate profile</title><link>https://peptidescanner.com/peptides/gallium-ga-68-dotatate/</link><guid isPermaLink="false">peptidescanner:whats-new:profile:gallium-ga-68-dotatate:v1</guid><description>A radioactive imaging agent built on dotatate, a cyclic eight-amino-acid peptide. FDA approved the NETSPOT kit in 2016 for PET scans that locate somatostatin receptor-positive neuroendocrine tumors. Site addition: 2026-11-16. Source checked: 2026-11-16. Limits: A source-linked profile account preserves the cited scope; it is not a complete review, treatment recommendation, or medical advice. Sources: NETSPOT (kit for the preparation of gallium Ga 68 dotatate injection) · SPL version 23 · published 2026-07-07 (https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&amp;setid=b2b3be70-17d8-4093-896c-f1c54a2cf242&amp;version=23); Drugs@FDA: NETSPOT (gallium dotatate Ga-68), NDA 208547 · original approval June 1, 2016 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=208547)</description><dc:date>2026-11-16</dc:date><category>Profile published</category><category>gallium-ga-68-dotatate</category></item><item><title>Glatiramer acetate profile</title><link>https://peptidescanner.com/peptides/glatiramer-acetate/</link><guid isPermaLink="false">peptidescanner:whats-new:profile:glatiramer-acetate:v1</guid><description>A mixture of synthetic polypeptides made from four amino acids, not a single peptide. FDA approved it as Copaxone in 1996 for relapsing forms of multiple sclerosis. Site addition: 2026-11-16. Source checked: 2026-11-16. Limits: A source-linked profile account preserves the cited scope; it is not a complete review, treatment recommendation, or medical advice. Sources: COPAXONE (glatiramer acetate injection) · SPL version 36 · published 2026-06-26 (https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&amp;setid=aa88f583-4f5f-433b-80b4-1f4c9fb28357&amp;version=36); Glatiramer acetate substance identity record (https://precision.fda.gov/uniisearch/srs/unii/5M691HL4BO); Drugs@FDA: COPAXONE (glatiramer acetate), NDA 020622 · original approval December 20, 1996 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=020622)</description><dc:date>2026-11-16</dc:date><category>Profile published</category><category>glatiramer-acetate</category></item><item><title>Gonadorelin profile</title><link>https://peptidescanner.com/peptides/gonadorelin/</link><guid isPermaLink="false">peptidescanner:whats-new:profile:gonadorelin:v1</guid><description>The synthetic form of gonadotropin-releasing hormone. FDA approved it as Factrel in 1982 and Lutrepulse in 1989, and Drugs@FDA lists both as discontinued. Site addition: 2026-11-16. Source checked: 2026-11-16. Limits: A source-linked profile account preserves the cited scope; it is not a complete review, treatment recommendation, or medical advice. Sources: Efficacy and safety of intravenous pulsatile gonadotropin-releasing hormone: Lutrepulse for injection (1990) · PMID 2122733 (https://doi.org/10.1016/0002-9378(90)91441-e); Gonadorelin substance identity record (https://precision.fda.gov/uniisearch/srs/unii/9O7312W37G); Drugs@FDA: FACTREL (gonadorelin hydrochloride), NDA 018123 · original approval September 30, 1982 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=018123); Drugs@FDA: LUTREPULSE KIT (gonadorelin acetate), NDA 019687 · original approval October 10, 1989 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=019687); Certain bulk drug substances for use in compounding that may present significant safety risks (https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks); Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 (https://www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances); HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) (https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf)</description><dc:date>2026-11-16</dc:date><category>Profile published</category><category>gonadorelin</category></item><item><title>Humanin profile</title><link>https://peptidescanner.com/peptides/humanin/</link><guid isPermaLink="false">peptidescanner:whats-new:profile:humanin:v1</guid><description>A 24-amino-acid peptide identified in 2001 as protecting nerve cells from Alzheimer disease-related damage in the laboratory. No human studies and no FDA approval are reported. Site addition: 2026-11-16. Source checked: 2026-11-16. Limits: A source-linked profile account preserves the cited scope; it is not a complete review, treatment recommendation, or medical advice. Sources: A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer’s disease genes and Abeta (2001) · PMID 11371646 (https://doi.org/10.1073/pnas.101133498); Interaction between the Alzheimer’s survival peptide humanin and insulin-like growth factor-binding protein 3 regulates cell survival and apoptosis (2003) · PMID 14561895 (https://doi.org/10.1073/pnas.2135111100); Humanin substance identity record (https://precision.fda.gov/uniisearch/srs/unii/H975EUX36G); Certain bulk drug substances for use in compounding that may present significant safety risks (https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks); Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 (https://www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances); HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) (https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf)</description><dc:date>2026-11-16</dc:date><category>Profile published</category><category>humanin</category></item><item><title>IGF-1 LR3 profile</title><link>https://peptidescanner.com/peptides/igf-1-lr3/</link><guid isPermaLink="false">peptidescanner:whats-new:profile:igf-1-lr3:v1</guid><description>An engineered, 83-amino-acid form of the growth factor IGF-1, a protein, not a peptide, made as a laboratory research tool. No human studies and no FDA approval are reported. Site addition: 2026-11-16. Source checked: 2026-11-16. Limits: A source-linked profile account preserves the cited scope; it is not a complete review, treatment recommendation, or medical advice. Sources: Detection of His-tagged Long-R3-IGF-I in a black market product (2010) · PMID 20675162 (https://doi.org/10.1016/j.ghir.2010.07.001); IGF-1 LR3 does not promote growth in late-gestation growth-restricted fetal sheep (2025) · PMID 39679943 (https://doi.org/10.1152/ajpendo.00259.2024); Novel recombinant fusion protein analogues of insulin-like growth factor (IGF)-I indicate the relative importance of IGF-binding protein and receptor binding for enhanced biological potency (1992) · PMID 1378742 (https://doi.org/10.1677/jme.0.0080213); Long-(Arg3) insulin-like growth factor-I (IGF-1 LR3) substance identity record (https://precision.fda.gov/uniisearch/srs/unii/M9L22Y19H9); Certain bulk drug substances for use in compounding that may present significant safety risks (https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks); Definition of the Term “Biological Product” (final rule, February 21, 2020) · FR Doc. 2020-03505 (https://www.federalregister.gov/documents/2020/02/21/2020-03505/definition-of-the-term-biological-product); Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 (https://www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances); HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) (https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf)</description><dc:date>2026-11-16</dc:date><category>Profile published</category><category>igf-1-lr3</category></item><item><title>Mecasermin profile</title><link>https://peptidescanner.com/peptides/mecasermin/</link><guid isPermaLink="false">peptidescanner:whats-new:profile:mecasermin:v1</guid><description>Recombinant human IGF-1, a 70-amino-acid protein, not a peptide, approved by FDA in 2005 as Increlex to treat growth failure in children with severe primary IGF-1 deficiency. Site addition: 2026-11-16. Source checked: 2026-11-16. Limits: A source-linked profile account preserves the cited scope; it is not a complete review, treatment recommendation, or medical advice. Sources: INCRELEX (mecasermin) injection · SPL version 4 · published 2025-11-17 (https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&amp;setid=d5b2b0e1-c523-468d-9a0b-4ae4e4a8dbce&amp;version=4); Drugs@FDA: INCRELEX (mecasermin [rDNA origin]), application 021839 · original approval August 30, 2005 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=021839); Definition of the Term “Biological Product” (final rule, February 21, 2020) · FR Doc. 2020-03505 (https://www.federalregister.gov/documents/2020/02/21/2020-03505/definition-of-the-term-biological-product)</description><dc:date>2026-11-16</dc:date><category>Profile published</category><category>mecasermin</category></item><item><title>Metreleptin profile</title><link>https://peptidescanner.com/peptides/metreleptin/</link><guid isPermaLink="false">peptidescanner:whats-new:profile:metreleptin:v1</guid><description>A recombinant form of the hormone leptin, a 147-amino-acid protein, not a peptide, approved by FDA in 2014 as Myalept for complications of leptin deficiency in generalized lipodystrophy. Site addition: 2026-11-16. Source checked: 2026-11-16. Limits: A source-linked profile account preserves the cited scope; it is not a complete review, treatment recommendation, or medical advice. Sources: MYALEPT (metreleptin) for injection · SPL version 18 · published 2025-03-10 (https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&amp;setid=d3b50bbd-140b-425c-b5ec-d4682aad62bc&amp;version=18); Drugs@FDA: MYALEPT (metreleptin), application 125390 · original approval February 24, 2014 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=125390); Definition of the Term “Biological Product” (final rule, February 21, 2020) · FR Doc. 2020-03505 (https://www.federalregister.gov/documents/2020/02/21/2020-03505/definition-of-the-term-biological-product)</description><dc:date>2026-11-16</dc:date><category>Profile published</category><category>metreleptin</category></item><item><title>MK-677 profile</title><link>https://peptidescanner.com/peptides/mk-677/</link><guid isPermaLink="false">peptidescanner:whats-new:profile:mk-677:v1</guid><description>A small synthetic compound, not a peptide, also called ibutamoren, that prompts growth hormone release. FDA lists it among compounding substances that may present significant safety risks, citing congestive heart failure. Site addition: 2026-11-16. Source checked: 2026-11-16. Limits: A source-linked profile account preserves the cited scope; it is not a complete review, treatment recommendation, or medical advice. Sources: MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study (2011) · PMID 21067829 (https://doi.org/10.1016/j.archger.2010.10.004); The nonpeptide growth hormone secretagogue, MK-0677, activates hypothalamic arcuate nucleus neurons in vivo (1998) · PMID 9535057 (https://doi.org/10.1046/j.1365-2826.1998.00176.x); Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial (2008) · PMID 19015485 (https://doi.org/10.1212/01.wnl.0000335163.88054.e7); Ibutamoren mesylate (MK-677) substance identity record (https://precision.fda.gov/uniisearch/srs/unii/R90JB6QJ2B); Certain bulk drug substances for use in compounding that may present significant safety risks (https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks); October 29, 2024 Meeting of the Pharmacy Compounding Advisory Committee · minutes (https://www.fda.gov/media/185412/download); Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 (https://www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances); Federal Register notice 2024-21241 · published 2024-09-18 · Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List; Revisions to the Withdrawn or Removed List (https://www.govinfo.gov/content/pkg/FR-2024-09-18/pdf/2024-21241.pdf); HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) (https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf)</description><dc:date>2026-11-16</dc:date><category>Profile published</category><category>mk-677</category></item><item><title>Orforglipron profile</title><link>https://peptidescanner.com/peptides/orforglipron/</link><guid isPermaLink="false">peptidescanner:whats-new:profile:orforglipron:v1</guid><description>A small-molecule GLP-1 receptor agonist, not a peptide, approved by FDA in April 2026 as Foundayo for weight reduction in adults with obesity or overweight with a related condition. Site addition: 2026-11-16. Source checked: 2026-11-16. Limits: A source-linked profile account preserves the cited scope; it is not a complete review, treatment recommendation, or medical advice. Sources: FOUNDAYO (orforglipron) tablet, film coated · SPL version 10 · published 2026-08-13 (https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&amp;setid=8ac446c5-feba-474f-a103-23facb9b5c62&amp;version=10); Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (2025) · PMID 40960239 (https://doi.org/10.1056/NEJMoa2511774); Drugs@FDA: FOUNDAYO (orforglipron calcium), NDA 220934 · original approval April 1, 2026 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=220934)</description><dc:date>2026-11-16</dc:date><category>Profile published</category><category>orforglipron</category></item><item><title>PEG-MGF profile</title><link>https://peptidescanner.com/peptides/peg-mgf/</link><guid isPermaLink="false">peptidescanner:whats-new:profile:peg-mgf:v1</guid><description>A pegylated form of mechano growth factor, a synthetic 24-amino-acid peptide based on the insulin-like growth factor 1 precursor. FDA has identified no human exposure data, and no FDA approval is reported. Site addition: 2026-11-16. Source checked: 2026-11-16. Limits: A source-linked profile account preserves the cited scope; it is not a complete review, treatment recommendation, or medical advice. Sources: Minireview: Mechano-growth factor: a putative product of IGF-I gene expression involved in tissue repair and regeneration (2010) · PMID 20130113 (https://doi.org/10.1210/en.2009-1217); Mechano growth factor (IGF-1Ec peptide) substance identity record (https://precision.fda.gov/uniisearch/srs/unii/Q86M4KXC2P); Certain bulk drug substances for use in compounding that may present significant safety risks (https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks); Bulk drug substances nominated for use in compounding under section 503A (categories 1 to 3) · updated May 14, 2026 (https://www.fda.gov/media/94155/download); Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 (https://www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances); HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) (https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf)</description><dc:date>2026-11-16</dc:date><category>Profile published</category><category>peg-mgf</category></item><item><title>Peginesatide profile</title><link>https://peptidescanner.com/peptides/peginesatide/</link><guid isPermaLink="false">peptidescanner:whats-new:profile:peginesatide:v1</guid><description>A synthetic peptide-based drug for anemia in kidney disease, approved by FDA as Omontys in 2012. It was recalled in 2013 after fatal allergic reactions, and FDA withdrew its approval in 2019 at the company’s request. Site addition: 2026-11-16. Source checked: 2026-11-16. Limits: A source-linked profile account preserves the cited scope; it is not a complete review, treatment recommendation, or medical advice. Sources: Anaphylaxis and hypotension after administration of peginesatide (2014) · PMID 24849101 (https://doi.org/10.1056/NEJMc1400883); Peginesatide in patients with anemia undergoing hemodialysis (2013) · PMID 23343061 (https://doi.org/10.1056/NEJMoa1203165); Peginesatide for anemia in patients with chronic kidney disease not receiving dialysis (2013) · PMID 23343062 (https://doi.org/10.1056/NEJMoa1203166); Peginesatide substance identity record (https://precision.fda.gov/uniisearch/srs/unii/JX56W9N61Q); Drugs@FDA: OMONTYS (peginesatide acetate), NDA 202799 · original approval March 27, 2012 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=202799); Certain bulk drug substances for use in compounding that may present significant safety risks (https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks); Takeda Pharmaceuticals U.S.A., Inc.; Withdrawal of Approval of a New Drug Application for OMONTYS (peginesatide) Injection (February 13, 2019) · FR Doc. 2019-02146 (https://www.federalregister.gov/documents/2019/02/13/2019-02146/takeda-pharmaceuticals-usa-inc-withdrawal-of-approval-of-a-new-drug-application-for-omontys); Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 (https://www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances); HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) (https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf)</description><dc:date>2026-11-16</dc:date><category>Profile published</category><category>peginesatide</category></item><item><title>SLU-PP-332 profile</title><link>https://peptidescanner.com/peptides/slu-pp-332/</link><guid isPermaLink="false">peptidescanner:whats-new:profile:slu-pp-332:v1</guid><description>A small synthetic compound, not a peptide, that activates estrogen-related receptors and acted like exercise in mice. No human studies and no FDA approval are reported. Site addition: 2026-11-16. Source checked: 2026-11-16. Limits: A source-linked profile account preserves the cited scope; it is not a complete review, treatment recommendation, or medical advice. Sources: Synthetic ERRα/β/γ agonist induces an ERRα-dependent acute aerobic exercise response and enhances exercise capacity (2023) · PMID 36988910 (https://doi.org/10.1021/acschembio.2c00720); A synthetic ERR agonist alleviates metabolic syndrome (2024) · PMID 37739806 (https://doi.org/10.1124/jpet.123.001733); SLU-PP-332 (4-hydroxybenzoic acid 2-(2-naphthalenylmethylene)hydrazide) substance identity record (https://precision.fda.gov/uniisearch/srs/unii/5YW57G7ADL); Certain bulk drug substances for use in compounding that may present significant safety risks (https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks); Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 (https://www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances); HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) (https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf)</description><dc:date>2026-11-16</dc:date><category>Profile published</category><category>slu-pp-332</category></item><item><title>Tesofensine profile</title><link>https://peptidescanner.com/peptides/tesofensine/</link><guid isPermaLink="false">peptidescanner:whats-new:profile:tesofensine:v1</guid><description>A small synthetic drug, not a peptide, that blocks the reuptake of noradrenaline, dopamine and serotonin. It was studied in phase 2 trials for obesity and Parkinson disease, and no FDA approval is reported. Site addition: 2026-11-16. Source checked: 2026-11-16. Limits: A source-linked profile account preserves the cited scope; it is not a complete review, treatment recommendation, or medical advice. Sources: Tesofensine (NS 2330), a monoamine reuptake inhibitor, in patients with advanced Parkinson disease and motor fluctuations: the ADVANS Study (2008) · PMID 18474731 (https://doi.org/10.1001/archneur.65.5.577); Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial (2008) · PMID 18950853 (https://doi.org/10.1016/S0140-6736(08)61525-1); Expression of concern—effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial (2013) · PMID 23561987 (https://doi.org/10.1016/S0140-6736(13)60778-3); Weight loss produced by tesofensine in patients with Parkinson’s or Alzheimer’s disease (2008) · PMID 18356831 (https://doi.org/10.1038/oby.2008.56); Tesofensine substance identity record (https://precision.fda.gov/uniisearch/srs/unii/BLH9UKX9V1); Certain bulk drug substances for use in compounding that may present significant safety risks (https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks); Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 (https://www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances); HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) (https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf)</description><dc:date>2026-11-16</dc:date><category>Profile published</category><category>tesofensine</category></item><item><title>Thymopentin profile</title><link>https://peptidescanner.com/peptides/thymopentin/</link><guid isPermaLink="false">peptidescanner:whats-new:profile:thymopentin:v1</guid><description>A synthetic five-amino-acid fragment of thymopoietin, studied as an immune modulator. Randomized trials in the 1990s had mixed results, and no FDA approval is reported. Site addition: 2026-11-16. Source checked: 2026-11-16. Limits: A source-linked profile account preserves the cited scope; it is not a complete review, treatment recommendation, or medical advice. Sources: Impact of thymopentin on the incidence and severity of postoperative infection: a randomized controlled trial (1994) · PMID 8156337 (https://doi.org/10.1002/bjs.1800810216); A randomized controlled trial of thymopentin therapy in patients with chronic hepatitis B (1994) · PMID 7836705 (https://doi.org/10.1016/s0168-8278(05)80314-9); Safety and efficacy of thymopentin in zidovudine (AZT)-treated asymptomatic HIV-infected subjects with 200-500 CD4 cells/mm3: a double-blind placebo-controlled trial (1995) · PMID 7859140 (https://doi.org/10.1097/00042560-199503010-00009); Thymopentin substance identity record (https://precision.fda.gov/uniisearch/srs/unii/O3Y80ZF13F); Certain bulk drug substances for use in compounding that may present significant safety risks (https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks); Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 (https://www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances); HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) (https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf)</description><dc:date>2026-11-16</dc:date><category>Profile published</category><category>thymopentin</category></item><item><title>VK2735 profile</title><link>https://peptidescanner.com/peptides/vk2735/</link><guid isPermaLink="false">peptidescanner:whats-new:profile:vk2735:v1</guid><description>An experimental GLP-1 and GIP receptor dual agonist studied for weight management. In a 13-week phase 2 trial, average weight loss was 9.1% to 14.7%; no FDA approval is reported. Site addition: 2026-11-16. Source checked: 2026-11-16. Limits: A source-linked profile account preserves the cited scope; it is not a complete review, treatment recommendation, or medical advice. Sources: ClinicalTrials.gov record NCT07104383 · retained source version 2026-04-07:2c8e771eae38a675ce6f376d5c356c4c03943ee4ecfe103d4bbbfc65c43428cd (https://clinicaltrials.gov/study/NCT07104383); ClinicalTrials.gov record NCT07868835 · retained source version 2026-11-16:754cc17245a18215ce0d3940312a9a7ada00032d9098c9032f6a189cf2f02123 (https://clinicaltrials.gov/study/NCT07868835); Weekly subcutaneous VK2735, a GIP/GLP-1 receptor dual agonist, for weight management: phase 2, randomized, 13-week VENTURE study (2026) · PMID 41508550 (https://doi.org/10.1002/oby.70106); Certain bulk drug substances for use in compounding that may present significant safety risks (https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks); Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 (https://www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances); HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) (https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf)</description><dc:date>2026-11-16</dc:date><category>Profile published</category><category>vk2735</category></item><item><title>A Phase 3 Trial of Vosoritide in Children with Hypochondroplasia.</title><link>https://peptidescanner.com/stories/pubmed-pmid-42713641-vosoritide/</link><guid isPermaLink="false">peptidescanner:whats-new:source-record:pubmed-pmid-42713641-vosoritide:v2</guid><description>PubMed lists PMID 42713641 in NEJM evidence as Journal Article, Clinical Trial, Phase III, Randomized Controlled Trial, Multicenter Study, with publication-date metadata of 2026-09-09 (day precision). PeptideScanner associated the retained record with the identity slug vosoritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article&apos;s findings. Source record updated: PubMed revised the bibliographic metadata of PMID 42713641, with a metadata revision date of 2026-11-09. This version reports that observation; the earlier retained observation remains available as version 1. Site addition: 2026-11-16. Source date: Cited source date 2026-11-09. Source checked: 2026-11-16. Limits: This is a selected source-linked record. Its source date and collection date stay separate; inclusion does not establish that the source is current, complete, safe, or effective. Sources: A Phase 3 Trial of Vosoritide in Children with Hypochondroplasia. · retained source version 1:2026-11-09:current:661fc7a368b93a94cbf38f0f500a456e1c3435412041e6d46715a17783bed724 (https://pubmed.ncbi.nlm.nih.gov/42713641/)</description><dc:date>2026-11-16</dc:date><category>Source record updated</category><category>vosoritide</category></item><item><title>ClinicalTrials.gov record NCT04775082</title><link>https://peptidescanner.com/stories/clinicaltrials-gov-nct04775082-liraglutide/</link><guid isPermaLink="false">peptidescanner:whats-new:source-record:clinicaltrials-gov-nct04775082-liraglutide:v2</guid><description>PeptideScanner retained ClinicalTrials.gov record NCT04775082 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner&apos;s reviewed identity mapping was liraglutide. Source record updated: ClinicalTrials.gov posted a newer version of NCT04775082, with a registry update date of 2026-11-16. This version reports that observation; the earlier retained observation remains available as version 1. Site addition: 2026-11-16. Source date: Cited source date 2026-11-16. Source checked: 2026-11-16. Limits: This is a selected source-linked record. Its source date and collection date stay separate; inclusion does not establish that the source is current, complete, safe, or effective. Sources: ClinicalTrials.gov record NCT04775082 · retained source version 2026-11-16:76f5393c2feb9bc0c30a792786461560044658fb99e6e94992bd2440ad4ce177 (https://clinicaltrials.gov/study/NCT04775082)</description><dc:date>2026-11-16</dc:date><category>Source record updated</category><category>liraglutide</category></item><item><title>ClinicalTrials.gov record NCT05278208</title><link>https://peptidescanner.com/stories/clinicaltrials-gov-nct05278208-lutetium-lu-177-dotatate/</link><guid isPermaLink="false">peptidescanner:whats-new:source-record:clinicaltrials-gov-nct05278208-lutetium-lu-177-dotatate:v2</guid><description>PeptideScanner retained ClinicalTrials.gov record NCT05278208 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner&apos;s reviewed identity mapping was lutetium-lu-177-dotatate. Source record updated: ClinicalTrials.gov posted a newer version of NCT05278208, with a registry update date of 2026-11-16. This version reports that observation; the earlier retained observation remains available as version 1. Site addition: 2026-11-16. Source date: Cited source date 2026-11-16. Source checked: 2026-11-16. Limits: This is a selected source-linked record. Its source date and collection date stay separate; inclusion does not establish that the source is current, complete, safe, or effective. Sources: ClinicalTrials.gov record NCT05278208 · retained source version 2026-11-16:516842d0ad86c0b81b029177e9786f5f7ea463f2778ec86219d6cae0e7ac5d5c (https://clinicaltrials.gov/study/NCT05278208)</description><dc:date>2026-11-16</dc:date><category>Source record updated</category><category>lutetium-lu-177-dotatate</category></item><item><title>ClinicalTrials.gov record NCT05669664</title><link>https://peptidescanner.com/stories/clinicaltrials-gov-nct05669664-leuprolide/</link><guid isPermaLink="false">peptidescanner:whats-new:source-record:clinicaltrials-gov-nct05669664-leuprolide:v2</guid><description>PeptideScanner retained ClinicalTrials.gov record NCT05669664 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner&apos;s reviewed identity mapping was leuprolide. Source record updated: ClinicalTrials.gov posted a newer version of NCT05669664, with a registry update date of 2026-11-16. This version reports that observation; the earlier retained observation remains available as version 1. Site addition: 2026-11-16. Source date: Cited source date 2026-11-16. Source checked: 2026-11-16. Limits: This is a selected source-linked record. Its source date and collection date stay separate; inclusion does not establish that the source is current, complete, safe, or effective. Sources: ClinicalTrials.gov record NCT05669664 · retained source version 2026-11-16:f51e846025c33d2a6185a83c6915ed112fda6b9b5c9880bd640e171be3a0141c (https://clinicaltrials.gov/study/NCT05669664)</description><dc:date>2026-11-16</dc:date><category>Source record updated</category><category>leuprolide</category></item><item><title>ClinicalTrials.gov record NCT06015893</title><link>https://peptidescanner.com/stories/clinicaltrials-gov-nct06015893-semaglutide/</link><guid isPermaLink="false">peptidescanner:whats-new:source-record:clinicaltrials-gov-nct06015893-semaglutide:v2</guid><description>PeptideScanner retained ClinicalTrials.gov record NCT06015893 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner&apos;s reviewed identity mapping was semaglutide. Source record updated: ClinicalTrials.gov posted a newer version of NCT06015893, with a registry update date of 2026-11-16. This version reports that observation; the earlier retained observation remains available as version 1. Site addition: 2026-11-16. Source date: Cited source date 2026-11-16. Source checked: 2026-11-16. Limits: This is a selected source-linked record. Its source date and collection date stay separate; inclusion does not establish that the source is current, complete, safe, or effective. Sources: ClinicalTrials.gov record NCT06015893 · retained source version 2026-11-16:5f57241a3c0175fb796024a17c48915ba71da1ba3a25565b0e2cccdd16ecdd5c (https://clinicaltrials.gov/study/NCT06015893)</description><dc:date>2026-11-16</dc:date><category>Source record updated</category><category>semaglutide</category></item><item><title>ClinicalTrials.gov record NCT07220759</title><link>https://peptidescanner.com/stories/clinicaltrials-gov-nct07220759-cagrilintide/</link><guid isPermaLink="false">peptidescanner:whats-new:source-record:clinicaltrials-gov-nct07220759-cagrilintide:v2</guid><description>PeptideScanner retained ClinicalTrials.gov record NCT07220759 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner&apos;s reviewed identity mapping was cagrilintide. Source record updated: ClinicalTrials.gov posted a newer version of NCT07220759, with a registry update date of 2026-11-16. This version reports that observation; the earlier retained observation remains available as version 1. Site addition: 2026-11-16. Source date: Cited source date 2026-11-16. Source checked: 2026-11-16. Limits: This is a selected source-linked record. Its source date and collection date stay separate; inclusion does not establish that the source is current, complete, safe, or effective. Sources: ClinicalTrials.gov record NCT07220759 · retained source version 2026-11-16:3886cfa54022957a6b99ae64076533d7e3fa52893bbcff76a6c879cfc1b9ffeb (https://clinicaltrials.gov/study/NCT07220759)</description><dc:date>2026-11-16</dc:date><category>Source record updated</category><category>cagrilintide</category></item><item><title>ClinicalTrials.gov record NCT07843472</title><link>https://peptidescanner.com/stories/clinicaltrials-gov-nct07843472-petrelintide/</link><guid isPermaLink="false">peptidescanner:whats-new:source-record:clinicaltrials-gov-nct07843472-petrelintide:v2</guid><description>PeptideScanner retained ClinicalTrials.gov record NCT07843472 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner&apos;s reviewed identity mapping was petrelintide. Source record updated: ClinicalTrials.gov posted a newer version of NCT07843472, with a registry update date of 2026-11-16. This version reports that observation; the earlier retained observation remains available as version 1. Site addition: 2026-11-16. Source date: Cited source date 2026-11-16. Source checked: 2026-11-16. Limits: This is a selected source-linked record. Its source date and collection date stay separate; inclusion does not establish that the source is current, complete, safe, or effective. Sources: ClinicalTrials.gov record NCT07843472 · retained source version 2026-11-16:badab750128a1703566522fa63aad6d06cef78727a09290afc35bbac50cad975 (https://clinicaltrials.gov/study/NCT07843472)</description><dc:date>2026-11-16</dc:date><category>Source record updated</category><category>petrelintide</category></item><item><title>Development of chondroitin sulfate‑stabilized PLGA microspheres of exenatide via polarity gradient extraction.</title><link>https://peptidescanner.com/stories/pubmed-pmid-42709517-exenatide/</link><guid isPermaLink="false">peptidescanner:whats-new:source-record:pubmed-pmid-42709517-exenatide:v2</guid><description>PubMed lists PMID 42709517 in Pharmaceutical development and technology as Journal Article, with publication-date metadata of 2026-09-18 (day precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article&apos;s findings. Source record updated: PubMed revised the bibliographic metadata of PMID 42709517, with a metadata revision date of 2026-10-30. This version reports that observation; the earlier retained observation remains available as version 1. Site addition: 2026-11-16. Source date: Cited source date 2026-10-30. Source checked: 2026-11-16. Limits: This is a selected source-linked record. Its source date and collection date stay separate; inclusion does not establish that the source is current, complete, safe, or effective. Sources: Development of chondroitin sulfate‑stabilized PLGA microspheres of exenatide via polarity gradient extraction. · retained source version 1:2026-10-30:current:62a63971814bb423fbc37e1b457f5a356652b2fccf219a3ee6390cdcbbab4d60 (https://pubmed.ncbi.nlm.nih.gov/42709517/)</description><dc:date>2026-11-16</dc:date><category>Source record updated</category><category>exenatide</category></item><item><title>Dysregulated glucagon signaling contributes to hypoglycemia after vertical sleeve gastrectomy in mice.</title><link>https://peptidescanner.com/stories/pubmed-pmid-42270043-glucagon/</link><guid isPermaLink="false">peptidescanner:whats-new:source-record:pubmed-pmid-42270043-glucagon:v2</guid><description>PubMed lists PMID 42270043 in Molecular metabolism as Journal Article, Research Support, Non-U.S. Gov&apos;t, with publication-date metadata of 2026-06-10 (day precision). PeptideScanner associated the retained record with the identity slug glucagon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article&apos;s findings. Source record updated: PubMed revised the bibliographic metadata of PMID 42270043, with a metadata revision date of 2026-10-28. This version reports that observation; the earlier retained observation remains available as version 1. Site addition: 2026-11-16. Source date: Cited source date 2026-10-28. Source checked: 2026-11-16. Limits: This is a selected source-linked record. Its source date and collection date stay separate; inclusion does not establish that the source is current, complete, safe, or effective. Sources: Dysregulated glucagon signaling contributes to hypoglycemia after vertical sleeve gastrectomy in mice. · retained source version 1:2026-10-28:current:5cdddb6bb6fa1df3efddbff980cdb39ac8aeefa9934de8c455164247516327d3 (https://pubmed.ncbi.nlm.nih.gov/42270043/)</description><dc:date>2026-11-16</dc:date><category>Source record updated</category><category>glucagon</category></item><item><title>Influence of Social Media on Self-Medication Behavior: A Study on Ozempic Use Among Emirati University Students.</title><link>https://peptidescanner.com/stories/pubmed-pmid-42196730-semaglutide/</link><guid isPermaLink="false">peptidescanner:whats-new:source-record:pubmed-pmid-42196730-semaglutide:v2</guid><description>PubMed lists PMID 42196730 in International journal of environmental research and public health as Journal Article, Research Support, Non-U.S. Gov&apos;t, with publication-date metadata of 2026-05-12 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article&apos;s findings. Source record updated: PubMed revised the bibliographic metadata of PMID 42196730, with a metadata revision date of 2026-11-01. This version reports that observation; the earlier retained observation remains available as version 1. Site addition: 2026-11-16. Source date: Cited source date 2026-11-01. Source checked: 2026-11-16. Limits: This is a selected source-linked record. Its source date and collection date stay separate; inclusion does not establish that the source is current, complete, safe, or effective. Sources: Influence of Social Media on Self-Medication Behavior: A Study on Ozempic Use Among Emirati University Students. · retained source version 1:2026-11-01:current:1b19af9af51d5b05e743f7d0f9ee2dfaaedf16b072a5d403866141fa0aa75948 (https://pubmed.ncbi.nlm.nih.gov/42196730/)</description><dc:date>2026-11-16</dc:date><category>Source record updated</category><category>semaglutide</category></item><item><title>Interlaboratory Comparison of a Glucagon and Oxyntomodulin Immuno-LC-MS/MS Assay: Implications for Diabetes Research.</title><link>https://peptidescanner.com/stories/pubmed-pmid-42400596-glucagon/</link><guid isPermaLink="false">peptidescanner:whats-new:source-record:pubmed-pmid-42400596-glucagon:v2</guid><description>PubMed lists PMID 42400596 in Clinical chemistry as Journal Article, Comparative Study, with publication-date metadata of 2026-11-04 (day precision). PeptideScanner associated the retained record with the identity slug glucagon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article&apos;s findings. Source record updated: PubMed revised the bibliographic metadata of PMID 42400596, with a metadata revision date of 2026-11-04. This version reports that observation; the earlier retained observation remains available as version 1. Site addition: 2026-11-16. Source date: Cited source date 2026-11-04. Source checked: 2026-11-16. Limits: This is a selected source-linked record. Its source date and collection date stay separate; inclusion does not establish that the source is current, complete, safe, or effective. Sources: Interlaboratory Comparison of a Glucagon and Oxyntomodulin Immuno-LC-MS/MS Assay: Implications for Diabetes Research. · retained source version 1:2026-11-04:current:4f1cc17b37e087bf82f6f6bd0d9fcd1e8dc4028c935033b92688e95ee173ed59 (https://pubmed.ncbi.nlm.nih.gov/42400596/)</description><dc:date>2026-11-16</dc:date><category>Source record updated</category><category>glucagon</category></item><item><title>Management of patients with cardiovascular disease and overweight/obesity: expert opinion on semaglutide use.</title><link>https://peptidescanner.com/stories/pubmed-pmid-42469146-semaglutide/</link><guid isPermaLink="false">peptidescanner:whats-new:source-record:pubmed-pmid-42469146-semaglutide:v2</guid><description>PubMed lists PMID 42469146 in Nutrition, metabolism, and cardiovascular diseases : NMCD as Journal Article, Review, Consensus Statement, with publication-date metadata of 2026-07-16 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article&apos;s findings. Source record updated: PubMed revised the bibliographic metadata of PMID 42469146, with a metadata revision date of 2026-11-03. This version reports that observation; the earlier retained observation remains available as version 1. Site addition: 2026-11-16. Source date: Cited source date 2026-11-03. Source checked: 2026-11-16. Limits: This is a selected source-linked record. Its source date and collection date stay separate; inclusion does not establish that the source is current, complete, safe, or effective. Sources: Management of patients with cardiovascular disease and overweight/obesity: expert opinion on semaglutide use. · retained source version 1:2026-11-03:current:e2c7150106c88920904f80cacdf70a9a2afef27c01cfe6787f0f347f4641e09d (https://pubmed.ncbi.nlm.nih.gov/42469146/)</description><dc:date>2026-11-16</dc:date><category>Source record updated</category><category>semaglutide</category></item></channel></rss>
